Imaging Innovation
Prognosis
The announcement of Siemens Healthineers’ expanded Naeotom Alpha class of CT scanners marks a pivotal moment in diagnostic imaging. Three years after introducing the world’s first commercial photon-counting CT, this technology is moving from pioneering innovation to mainstream clinical tool.
With more than a million patients scanned worldwide since 2021, the evidence base for this technology’s clinical value is compelling. The introduction of a single-source version alongside the dual-source scanner represents more than just product line expansion – it signals the technology’s maturation and readiness for broader clinical adoption.
What makes this development particularly significant is its timing. Healthcare systems globally face mounting pressures: rising patient volumes, workforce constraints, and the need for more precise diagnostics to support increasingly personalised treatment pathways. Photon-counting CT addresses these challenges head-on by potentially reducing the need for invasive procedures, enabling earlier diagnosis, and supporting more confident clinical decisionmaking.
The technology’s ability to reduce radiation dose by up to 40% while delivering superior image quality represents a genuine advance in patient care. For cardiologists, the ability to clearly visualise heavily calcified vessels or stented segments without invasive catheterisation could transform diagnostic pathways. For paediatricians, lower radiation doses open new diagnostic possibilities.
These developments suggest we’re witnessing a fundamental shift in CT imaging, not just an incremental improvement. As Prof. Gabriel Krestin of Erasmus Medical Center predicts, “In the future, every CT will be a photoncounting CT.”
The real test will come as these systems are deployed across different healthcare settings. With Siemens Healthineers investing €80 million in detector production, they’re clearly betting on widespread adoption. If the technology delivers on its promise, we may look back on this period as the moment when photon-counting CT came of age, marking the start of a new era in diagnostic imaging.
If you are visiting the Arab Health exhibition in Dubai, Middle East Health will be there at booth MS.B36 – pop by and say hello.
Callan Emery Editor editor@MiddleEastHealth.com
Publisher Michael Hurst Michael@MiddleEastHealth.com
Editor Callan Emery editor@MiddleEastHealth.com
Editorial Consultants Dr Gamal Hammad, Dr Peter Moore, Harry Brewer
Middle East Editorial Office PO Box 72280, Dubai, UAE Telephone: (+9714) 391 4775 editor@MiddleEastHealth.com
Marketing Manager Foehn Sarkar Telephone: (+9714) 391 4775 n Fax: (+9714) 391 4888 marketing@MiddleEastHealth.com
Subscription & Admin Manager Savita Kapoor Telephone: (+9714) 391 4775 n Fax: (+9714) 391 4888 Savita@MiddleEastHealth.com
Advertising Sales PO Box 72280, Dubai, UAE marketing@MiddleEastHealth.com
Americas, France
Joy Sarkar P O Box 72280, Building No.2 2nd Floor, Dubai Media City Dubai, United Arab Emirates Tel: +971 4 391 4775 Fax: +971 4 391 4888 Joy@MiddleEastHealth.com
Japan
Mr Katsuhiro Ishii
Ace Media Service Inc 12-6, 4-chome, Adachi-ku, Tokyo 121-0824, Japan Tel: +81-3-5691-3335 n Fax:+81-3-5691-3336 Email: amskatsu@dream.com
China
Miss Li Ying
Medic Time Development Ltd, Flat 1907, Tower A, Haisong Building, Tairan 9th Road, Futian District, Shenzhen, China 518048 Tel: +86-755-239 812 21 n Fax: +86-755-239 812 33 Email: medic8@medictime.com
Taiwan
Larry Wang
Olympia Global Co Ltd 7F, No.35, Sec 3, Shenyang Rd, Taichung Taiwan 40651 n P O Box: 46-283 Taichung Taiwan 40799
Tel: +886- (4)-22429845 n Fax:+886- (4)-23587689 Email: media.news@msa.hinet.net
Middle East Health is published by Hurst Advertising FZ LLC Dubai Media City, License Number: 30309
UAE National Media Council - Approval Number: 2294781.
Middle East Health online www.MiddleEastHealth.com is printed by Masar Printing and Publishing. www.masarprint.com
28 Cardiology: The human heart can repair itself when given a helping hand
32 Cardiology: The heart’s hidden brain: Complex neural network discovered controlling cardiac rhythm
44 Medical Imaging: Siemens Healthineers expands revolutionary photoncounting CT portfolio with new scanner class
45 Medical Imaging: Photon-counting CT transforms cardiac diagnostics pathway
48 Medical Imaging: New radiotracer technology advances cancer detection and treatment planning
50 Medical Imaging: Novel imaging technique reveals treatment-resistant lung cancers
43 Faecal microbiota transplantation shows promise for diabetic gastroenteropathy
66 New test brings precision forecasting to early-stage lung cancer outcomes
80 Deep sleep’s brain-cleaning system revealed in landmark study
Cover Image: A CT image of the human heart acquired with Siemens Healthineers’ new photoncounting CT, Naeotom Alpha. The system’s ability to provide comprehensive diagnostic information in a single scan – including calcium scoring, coronary vessel analysis, and spectral data – can significantly streamline the diagnostic pathway. This consolidation of imaging needs can reduce the time from initial presentation to treatment decision, as well as reduce the need for invasive diagnostic procedures.
Image courtesy of University Hospital, Switzerland
middle east monitor
Update from around the region
First robotic mastectomy performed in UAE at Cleveland Clinic Abu Dhabi
Cleveland Clinic Abu Dhabi has achieved a significant milestone by performing the first robotic mastectomy in the United Arab Emirates, marking a technical advancement in breast cancer surgery within the region. The procedure, also a first across the global Cleveland Clinic network, introduces a minimally invasive surgical option for carefully selected breast cancer patients.
Technical advances enhance surgical precision
The surgery, performed using the Da Vinci single-port robotic system, enables surgeons to complete the mastectomy through a small incision under the armpit, preserving nerve function while allowing simultaneous breast reconstruction. This technical approach represents a departure from traditional mastectomy procedures, which typically require larger chest incisions.
Dr. Ahmad Matalkah, staff physician at Cleveland Clinic Abu Dhabi’s Breast Surgery Program, who led the surgical team, explains: “Robotic breast surgery has been gaining momentum worldwide due to its precision, minimize scarring, and faster recovery times and can be offered to selected patients with breast cancer or risk
reducing mastectomy in patients with ge netic mutations.”
Patient selection criteria remain crucial The surgical team emphasises that patient selection is critical for successful outcomes. “Eligibility for robotic mastectomy depends on factors such as tumor size, body size, location, and overall patient health. Our team carefully evaluates each case to determine the best approach for the patient’s individual needs,” notes Dr. Matalkah.
botic surgery experts. This preparation ensures the safe application of the technology while maintaining surgical standards.
The procedure integrates reconstruction capabilities, as outlined by Dr. Tibor G Kovacs, staff physician: “Robotic mastectomy allows patients to restore their breast shapes with the help of an implant-based breast reconstruction, providing both physical and emotional benefits.”
The introduction of robotic mastectomy adds to Cleveland Clinic Abu Dhabi’s existing portfolio of robotic-assisted procedures across multiple surgical specialties, including transplantation and cardiac surgery. This technological implementation aims to expand the surgical options available to breast cancer patients in the region while maintaining oncological safety standards.
Dr. Ahmad Matalkah, staff physician at Cleveland Clinic Abu Dhabi’s Breast Surgery Program
King’s College Hospital London - Dubai launches pioneering paediatric liver transplant service
King’s College Hospital London - Dubai has established the first dedicated paediatric and adult liver transplant centre in Dubai, building upon four decades of hepatological expertise. The facility, which opened in November 2024, represents a significant development in specialist healthcare provision within the United Arab Emirates.
The centre is led by Professor Mohamed Rela, who brings substantial technical experience having performed over 4,000 liver transplants. His expertise includes pioneering work in paediatric liver transplantation, notably holding a world record for transplanting a liver in a five-day-old infant.
The facility implements a multidisciplinary approach, integrating hepatologists, surgeons, psychologists, and dietitians to provide comprehensive patient care. This model builds upon established protocols from King’s College Hospital London, which performs over 200 transplants annually and ranks among the world’s top three liver transplant centres.
The centre’s establishment addresses a critical healthcare gap in the region, particularly for paediatric cases involving conditions such as biliary atresia. Through partnerships with organisations including Al Jalila Foundation, the facility aims to improve access to transplant procedures for families facing financial constraints.
The initiative traces its origins to 1979, when Sheikh Zayed bin Sultan Al Nahyan provided funding for the King’s Liver Research Centre in London. This latest development expands upon the adult liver transplant service launched in Dubai in 2023, operating under the regulatory
Sharjah’s Zayed Military Hospital expanded and renamed
oversight of the Ministry of Health and Prevention and Dubai Health Authority.
Dr Tashfeen Siddiq Ali, Chief Medical Officer at King’s, emphasises the centre’s preventative approach: “This Centre is not only providing treatment for liver diseases and transplant but also has a comprehensive programme for early detection and prevention of liver diseases.”
The establishment of this specialist unit aligns with the UAE’s broader healthcare development objectives, in an effort to reduce the need for international medical travel while maintaining equivalent clinical standards to those available in the UK.
Zayed Military Hospital, a prominent military healthcare facility in Sharjah, UAE, will undergo a significant transition and be renamed Sheikh Sultan bin Zayed Hospital, marking its expansion to serve both military personnel and civilian communities in the UAE’s northern regions from January 2025.
The 200-bed facility, managed by healthcare technology company M42 in collaboration with the UAE Ministry of Defence, represents a novel military-civilian partnership in the region. The hospital, spanning 45,000 square metres, houses comprehensive medical facilities including six operating theatres, an in-house laboratory, pharmacy, radiology department, emergency care, and intensive care units.
Clinical expertise will be drawn from M42’s established network, including Imperial College London Diabetes Centre, Amana Healthcare, Mubadala Health Dubai, and Healthpoint. The facility will offer special-
ised services in family and internal medicine, diabetes management, endocrinology, cardiology, neurology, orthopaedics, gastroenterology, and urology.
Dr Aysha Sultan Aldhaheri, Major General and Executive Director of the Military Health Executive Directorate in the UAE Ministry of Defence, commented: “This cooperation clearly demonstrates our unwavering commitment to providing the highest standards of healthcare to the armed forces, while enhancing our role in the national health system by improving access to specialized medical care to a larger segment of the society.”
The expansion aims to address the
healthcare needs of communities in the northern regions who currently travel considerable distances to access specialist medical services. The hospital plans to implement targeted health programmes, including educational initiatives and comprehensive health screenings, tailored to local community requirements.
M42, established in 2022 through the merger of G42 Healthcare and Mubadala Health, operates more than 450 facilities across 26 countries. The organisation employs over 20,000 staff and manages several prominent healthcare facilities in the UAE, including Cleveland Clinic Abu Dhabi and Moorfields Eye Hospital Abu Dhabi.
King s Liver Transplant Centre of Excellence inauguration
Mecomed launches network to promote leadership of women in Middle East MedTech
The Medical Technology Association in the Middle East and Africa (Mecomed) has established the Women in MedTech Network (WMN), addressing the significant gender disparity in the region’s medical technology leadership. Current data indicates women occupy merely 1% of CEO positions in the Middle Eastern and African MedTech sector, highlighting the pressing need for initiatives supporting female advancement in the industry.
Strategic development programme
The network’s framework encompasses structured mentorship programmes and professional development resources, specifically designed to enhance leadership capabilities among women in the medical technology sphere. This systematic approach aims to create sustainable pathways for women to advance into senior positions within the sector.
The initiative represents a strategic response to the documented underrepresentation of women in MedTech leadership roles across the Middle East and Africa. Farah N. Hamdan, Mecomed Board Member and CEEMA GM at Zimmer Biomet, emphasised the correlation between diversity and medical technology advancement, stating: “We believe that diversity and inclusion are essential to innovation and advancement in MedTech.”
Industry impact assessment
Mecomed CEO Rami Rajab highlighted the strategic importance of addressing gender disparity in leadership positions, noting that the exceptionally low percentage of female CEOs in the sector necessitates targeted intervention. The programme’s implementation is expected to influence innovation trajectories and healthcare outcomes across the region through increased diversity in decision-making positions.
The WMN initiative aligns with broader industry efforts to enhance healthcare delivery through diverse leadership perspectives. The network’s establishment marks a structured approach to developing a talent pipeline for female leadership in the medical technology sector, potentially influencing future innovation and market dynamics in the region.
The programme’s launch featured comprehensive sessions outlining operational frameworks and mentorship structures, establishing foundational elements for sustained professional development. This systematic approach to supporting female advancement in MedTech leadership positions represents a measurable step towards addressing documented gender disparities in the sector.
Mecomed, serving as the principal trade association for medical devices, imaging, and diagnostics manufacturers in the Middle East and Africa, positions this initiative within its broader mandate to enhance healthcare delivery through strategic industry development. The association maintains collaborative relationships with governmental bodies, regional organisations, and healthcare professionals to advance medical technology implementation across the region.
Sheikh Shakhbout Medical City gains first academic medical centre status in Abu Dhabi
The UAE’s Sheikh Shakhbout Medical City (SSMC) has achieved Joint Commission International’s (JCI) Academic Medical Centre Accreditation, becoming Abu Dhabi’s first hospital to receive this distinguished recognition. The achievement positions SSMC at the forefront of medical education and research in the region.
The accreditation process evaluated SSMC’s performance across multiple domains, with particular emphasis on medical education, clinical research and quality improvement. The hospital demonstrated comprehensive adherence to JCI’s stringent international standards for healthcare quality and patient safety.
The 714-bed tertiary care facility has established itself as a crucial training hub, maintaining active partnerships with three medical schools and serving as a primary
training site for medical students and postgraduate trainees in the UAE.
Dr. Marwan Al Kaabi, chief executive officer at SSMC, said: “Receiving JCI’s ‘Gold Seal of Approval’ is more than just a milestone for SSMC, it reflects our dedication to maintaining the highest standards of healthcare on a global level. The JCI accreditation is widely recognised as the gold standard for quality and safety in the healthcare industry, underscoring our commitment to providing world-class care.”
Research and education integration
The hospital’s clinical research programme operates under multiple approved protocols, engaging patients in studies that contribute to medical knowledge advancement. SSMC’s educational initiatives incorporate modern technology and maintain partnerships with leading academic institutions, fostering an environment conducive to medical learning and innovation.
Dr. Abdulkarim Saleh, dean of Education at SSMC, emphasised the significance of this
recognition: “This prestigious accreditation is testament to our steadfast commitment to excellence in healthcare innovation, education and research, placing SSMC among the elite healthcare institutions, globally.”
The facility operates 18 operating theatres, including a hybrid operating room and a 26-bed neonatal intensive care unit, offering care across 46 medical specialties. As a subsidiary of PureHealth,
the largest healthcare group in the Middle East, SSMC’s achievement reinforces the UAE’s position in advancing medical education and research standards in the region.
Mediclinic Middle East honours outstanding medical educators
Medical educators at Mediclinic Middle East have been recognised for their exceptional contributions to clinical training and research at the second annual Excellence Awards ceremony, held in collaboration with Mohammed Bin Rashid University of Medicine and Health Sciences (MBRU) in Dubai.
The awards, which took place on 22 November 2024, acknowledge the critical role of Mediclinic staff in training MBRU’s medical students, nursing trainees, and postgraduate residents. Dr Gerasmos Capatos, Consultant Intensivist at Mediclinic Parkview Hospital and Adjunct Clinical Assistant Professor at MBRU, received the prestigious Dr Edwin Hertzog Outstanding Educator of the Year Award for 2023-2024. The selection process involved careful consideration of student nominations by a joint panel of Mediclinic and MBRU judges.
The awards ceremony also saw Dr Paddy Kilian receive The Outstanding Leadership in Healthcare Education award for her instrumental role in strengthening the academic partnership between the two institutions. This collaboration, now in its eighth year, provides MBRU students with hands-on clinical experience across Mediclinic’s Dubai facilities whilst enabling participation in research projects led by experienced physicians.
Dr Amer Sharif, Chief Executive Officer
demic partnership, stating it “is a real illustration of how an integrated academic health system benefits the public and is testament to our learning and discovery missions at Dubai Health”.
Hein van Eck, Chief Executive Officer of Mediclinic Middle East, highlighted the educators’ commitment, noting that “it is their passion for teaching which makes our partnership with MBRU so
meaningful, as we work together to deliver exceptional education for the UAE’s healthcare professionals of tomorrow”.
The excellence awards programme includes categories such as Educator of the Year, Star, and Outstanding Leadership in Healthcare Education, recognising various aspects of medical education and mentorship. This initiative reflects the growing emphasis on structured clinical training and academic medicine in the UAE’s healthcare sector.
Dr. Marwan Al Kaabi, chief executive officer at SSMC
worldwide monitor
Update from around the globe
Malaria cases surge globally despite prevention advances
Despite averting an estimated 2.2 billion cases and 12.7 million deaths since 2000, malaria continues to pose a significant global health challenge, with the WHO African Region bearing a disproportionate burden of the disease. Recent data from the World Health Organization reveals 263 million cases and 597,000 deaths worldwide in 2023, marking an increase of 11 million cases from the previous year.
Since 2000, the landscape of malaria con trol has transformed significantly, with 44 countries and one territory achiev ing WHO malaria-free certification. The number of countries reporting fewer than 10 annual cases has increased dramatically from four in 2000 to 25 in 2023, demon strating successful elimination strategies in multiple regions.
Persistent challenges in high-burden countries
The WHO African Region, while achiev ing a 16% reduction in mortality rates since 2015, continues to face substantial challenges. The current mortality rate of 52.4 deaths per 100,000 population remains more than double the target set by the Global technical strategy for ma laria 2016-2030. This persistent gap has prompted coordinated action among 11 high-burden African nations, which collectively account for two-thirds of global malaria cases.
Recent developments in malaria prevention tools have shown promising results. The introduction of malaria vaccines through routine childhood immunisation programmes in 17 countries represents a significant advancement in protection strategies. Additionally, new-generation insecticide-treated nets have demonstrated superior efficacy compared to traditional pyrethroid-only variants. In 2023, these advanced nets constituted 78% of the 195 million nets delivered to sub-Saharan Africa, marking a substantial increase from 59% in 2022.
Funding deficit impacts implementation
Despite technological progress, funding
remains a critical barrier to effective malaria control. The 2023 global funding allocation of US$ 4 billion falls significantly short of the US$ 8.3 billion target established by the Global technical strategy. This shortfall has resulted in substantial gaps in the distribution of essential preventive tools, particularly affecting vulnerable populations.
WHO Director-General Dr Tedros Adhanom Ghebreyesus emphasised the ongoing disparities, stating: “No one should die of malaria; yet the disease continues to disproportionately harm people living in the African region, especially young children and pregnant women.”
Beyond financial constraints, malariaendemic countries face multiple challenges, including fragile health systems, inadequate surveillance infrastructure, and emerging biological threats such as drug
and insecticide resistance. Environmental factors, including climate change and natural disasters, further compound these challenges, particularly affecting vulnerable populations such as pregnant women, children under five years, and communities in remote areas with limited healthcare access.
The WHO emphasises the necessity of strengthening primary healthcare systems and addressing underlying health determinants, including gender inequities. The organisation advocates for enhanced data systems capable of monitoring health inequalities through detailed demographic analysis. These recommendations align with a broader strategy to ensure that antimalarial innovations are developed with direct input from affected communities, emphasising equity, gender equality, and human rights in their design and implementation.
Experts call for focus on rising heart risks from cancer treatments
Cardiologists are calling for urgent attention to heart-related side effects of cancer treatments, as new data suggests approximately one-third of patients experience cardiovascular complications. The European Society of Cardiology (ESC) has announced a dedicated conference to address what experts describe as a potential ‘cardio-oncology epidemic’.
The intersection of cancer treatment and cardiovascular health presents an increasing challenge for healthcare systems. According to research published in the European Heart Journal, 32% of patients develop mild cardiac toxicities that could worsen without proper monitoring, while 6% experience moderate to severe complications.
Dr Teresa López-Fernandez from University Hospital La Paz, Madrid, emphasises the critical nature of this emerging medical subspecialty: “The main goal of this emerging specialty of cardio-oncology is to reduce the burden of CVD in cancer patients allowing them to receive the best anticancer therapy with the lowest rate of side effects and treatment interruptions.”
Demographics drive increasing risks
The rising prevalence of cardiovascular complications stems from multiple factors, in-
cluding an ageing population and increasing cancer diagnoses requiring long-term therapy. Dr Alexander Lyon from Royal Brompton Hospital, London, notes that the combination of growing cancer survivor populations and patients over 65 requiring chronic cancer treatment is creating unprecedented challenges for healthcare providers.
In response to these concerns, the ESC established its Council of Cardio-Oncology in 2018, which has grown to include more than 2,000 members worldwide. The council published the first ESC Clinical Practice Guidelines on cardio-oncology in 2022, providing comprehensive recommendations for cardiovascular toxicity risk assessment, preventive strategies, and monitoring protocols.
Collaborative approach shapes future care
The guidelines emphasise the importance
of early intervention and close collaboration between cardiology and oncology teams. When cardiac dysfunction is detected, specialists must carefully weigh the benefits and risks of continuing cancer treatment. “Our mission is always to ensure that cancer patients have the best and most effective cancer treatment safely, and to prevent interruptions in their cancer treatment due to cardiovascular problems which could have been prevented,” explains Dr Lyon.
The inaugural ESC Cardio-Oncology conference, scheduled for June 2025 in Florence, Italy, will bring together international experts to address these challenges. The conference will feature updates from the RESILIENCE Trial, an EU-funded study investigating new strategies to prevent anthracycline cardiotoxicity.
New global estimates reveal more than 20% of adults worldwide living with genital herpes
The first comprehensive WHO analysis since 2016 shows one in five adults aged 15-49 years are living with genital herpes infection, with 42 million new cases occurring annually. The findings underscore urgent need for novel therapeutic approaches and preventive strategies.
Treatment gaps persist as infections rise
The World Health Organization’s latest analysis reveals a significant burden of genital herpes infections globally, with approximately 846 million individuals aged 15-49 years affected. The research, published in Sexually Transmitted Infections, demonstrates that whilst HSV-2 prevalence remains stable since 2016, genital HSV-1 infections have increased.
The study identifies 520 million cases of genital HSV-2 infection, traditionally associated with sexual transmission, and 376 million cases of genital HSV-1 infection in 2020. Notably, 50 million individuals harbour concurrent infections with both viral types.
Changing transmission patterns emerge
Recent epidemiological data suggest evolving transmission dynamics for HSV-1. Several countries report declining childhood oral infections alongside increasing adult genital infections. Researchers attribute this shift to improved living conditions and hygiene practices, which paradoxically increase susceptibility to genital infection in later life.
Dr Meg Doherty, Director of Global HIV, Hepatitis and Sexually Transmitted Infections Programmes at WHO, emphasises the broader healthcare implications:
“While most people with a genital herpes infection experience few symptoms,
with so many infections genital herpes still causes pain and distress for millions globally and strains already overburdened health systems.”
Economic impact and clinical burden
The infection’s economic impact is substantial, with recent research indicating annual global costs of US$35 billion, encompassing both healthcare expenditure and productivity losses. Clinical manifestations affect over 200 million individuals annually, with symptoms including recurrent genital ulceration requiring multiple healthcare interventions.
HSV-2 presents particular public health challenges, accounting for approximately
90% of symptomatic episodes and correlating with a threefold increased risk of HIV acquisition. Additionally, whilst rare, neonatal herpes remains a serious concern, particularly when primary infection occurs during late pregnancy.
Research priorities and prevention strategies
Dr Sami Gottlieb, Medical Officer within WHO’s Department of Sexual and Reproductive Health and Research, highlights the need for enhanced research efforts: “Stigma around genital herpes means it
has been discussed too little, despite affecting millions of people globally. Not enough has been done to address this common infection.”
Current prevention strategies focus on barrier protection and abstention from sexual contact during symptomatic periods. WHO recommendations include HIV testing for symptomatic individuals and consideration of pre-exposure prophylaxis where indicated.
The organisation’s Global Health Sector Strategy for 2022-2030 emphasises increasing awareness, improving access
to antivirals, and promoting HIV prevention. Additionally, WHO is actively supporting research into novel preventive tools, including vaccines, treatments, and topical microbicides.
The study methodology incorporated comprehensive regional systematic reviews and meta-analyses of HSV-1 and HSV-2 prevalence across all WHO regions. This approach enabled researchers to estimate both prevalence and incidence of genital HSV infection and related genital ulcer disease globally and regionally for 2020.
Measles infections reach 10.3 million globally as vaccination gaps persist
Inadequate immunisation rates have driven global measles infections to 10.3 million cases in 2023, marking a 20% increase from the previous year, according to new data released by the World Health Organization (WHO) and US Centers for Disease Control and Prevention (CDC). The figures highlight concerning gaps in global vaccination coverage, with more than 22 million children missing their first dose of measles vaccine last year.
Despite a modest 8% reduction in deaths compared to 2022, measles claimed an estimated 107,500 lives in 2023, predominantly affecting children under five years of age. The reduction in mortality, whilst the number of cases increased, is attributed to the geographical distribution of outbreaks occurring in regions with better access to healthcare and nutrition.
The surge in cases has affected multiple WHO regions, with 57 countries experiencing significant outbreaks – a 60% increase from 36 countries in 2022. The African region bore a disproportionate burden, accounting for nearly half of all major outbreaks. Notable increases were also observed across the Eastern Mediterranean, European, South-East Asia and Western Pacific regions.
Vaccination coverage challenges
Current global vaccination rates re-
main substantially below the 95% coverage threshold required for effective population protection. Data indicates that 83% of children received their initial measles vaccine dose in 2023, while second-dose coverage reached only 74%. Dr Tedros Adhanom Ghebreyesus, WHO Director-General, emphasised the vaccine’s historical impact, saying: “Measles vaccine has saved more lives than any other vaccine in the past 50 years.”
The surge in cases threatens progress towards the elimination targets outlined in Immunization Agenda 2030. However, some positive developments have emerged, with 82 countries achieving or maintaining measles elimination by the end of 2023. Brazil’s recent reverification of elimination status has restored the Americas Region to measles-free status.
Future interventions
Health authorities are calling for targeted interventions, particularly in the
African and Eastern Mediterranean regions, and in fragile, conflict-affected areas. These efforts must encompass both routine immunisation programmes and high-quality vaccination campaigns. Additionally, strengthening disease surveillance systems, including the Global Measles Rubella Laboratory Network, remains crucial for rapid outbreak detection and response.
The implications of measles infection extend beyond immediate mortality risk, with potential long-term complications including blindness, pneumonia, and encephalitis, particularly affecting infants and young children. CDC Director Mandy Cohen emphasised the critical role of vaccination, stating: “The measles vaccine is our best protection against the virus, and we must continue to invest in efforts to increase access.”
Medical research news from around the world the laboratory
Magnetic microrobots offer new approach to treating fallopian tube blockages
A magnetically controlled microscopic robot that can clear obstructions in fallopian tubes has been developed by researchers, potentially offering a less invasive treatment option for a common cause of infertility.
Scientists at the SIAT Magnetic Soft Microrobots Lab have engineered a miniature robotic device designed to navigate and clear blockages within fallopian tubes. The research, published in AIP Advances on December 17, 2024, demonstrates how magnetic control systems could provide more precise and gentler approaches to treating tubal infertility.
The microscrew-shaped robot consists of a nonmagnetic photosensitive resin base coated with iron, allowing it to be precisely controlled using external magnetic fields. This coating enables the device to rotate and generate forward motion through narrow channels that simulate fallopian tube structures.
Innovative design features
The robot’s architecture incorporates several key elements that enhance its functionality. A helical body structure provides the primary propulsion mechanism, while a cylindrical central tube and disk-shaped tail work together to stabilise movement and aid debris clearance.
“This new technology offers a potentially less invasive alternative to the traditional surgical methods currently used to clear tubal obstructions, which often involve the use of conventional catheters and guidewires,” explained author Haifeng Xu.
The team’s testing demonstrated how the rotating motion of the microscrew generates a vortex effect that helps move fragmented material away from blockage sites, improving the efficiency of the clearance process.
Clinical significance
Fallopian tube obstruction represents a significant factor in female infertility, contributing to between 11% and 67% of cases worldwide. Current treatments typically rely on surgical interventions using traditional medical instruments, which can be more invasive and potentially traumatic to the delicate tubal structures.
The development of this microrobotic system could provide clinicians with more precise tools for treating tubal blockages, potentially reducing procedure-related
complications and improving outcomes for patients seeking fertility treatment.
Future developments
The research team has outlined several areas for future development, including further miniaturisation of the device and integration with in vivo imaging systems to enable real-time tracking during procedures. They also plan to conduct testing using isolated organ models to better understand the robot’s performance in more realistic biological conditions.
“The ultimate goal is to provide a more effective, minimally invasive solution for patients suffering from infertility,” said Xu.
The team is also exploring the potential for developing automated control systems that could enhance the efficiency of blockage removal procedures, with possible applications extending to other areas of microsurgery.
With an estimated 186 million people worldwide affected by infertility, the development of less invasive and more precise treatment options could have significant implications for reproductive medicine and patient care.
Reference: Liu, X., Liu, Y., Huang, J., et. al. (2024). Magnetically driven robotic microscrew for the oviduct recanalization. AIP Advances https://doi.org/10.1063/5.0233734
Mini-brain models advance understanding of mitochondrial disease mechanisms
Research team at the University of Bergen develops brain organoids to study mitochondrial dysfunction, offering new insights into neurological conditions including severe epilepsy and neurodegenerative diseases.
Scientists have achieved a significant advance in understanding mitochondrial diseases through the development of sophisticated brain organoid models that replicate key aspects of cellular energy dysfunction. The research, published in Advanced Science on 6 March 2024, demonstrates how these ‘mini-brains’ can effectively model the complex pathological features associated with mitochondrial disorders.
Understanding cellular powerhouse failure
The study, conducted at the University of Bergen’s Department of Clinical Medicine, focuses on the critical role of mitochondria in neurological function. These cellular organelles, essential for energy production, are particularly crucial in brain tissue, where energy demands are exceptionally high. When mitochondrial function is compromised, it can lead to severe neurological manifestations, including epilepsy and potentially contribute to neurodegenerative conditions.
Modelling disease progression
The research team, led by Group Leader Kristina Xiao Liang, has successfully de-
veloped brain organoids that accurately mirror the cellular and molecular consequences of mitochondrial dysfunction.
“The mini-brains give us a unique opportunity to understand disease mechanisms at the cellular level and test potential treatments. This is a significant step towards developing new therapies for diseases like severe epilepsy,” explains Liang.
Applications in neurodegenerative research
Beyond their immediate application in studying mitochondrial diseases, these organoid models show promise for investigating other neurological conditions. The research suggests potential applications in studying Alzheimer’s and Parkinson’s disease, where mitochondrial dysfunction has been implicated in disease progression.
“These diseases often involve mitochondrial dysfunction that can be studied in the mini-brains. They allow researchers to study disease progression in real time, test personalized therapies, and identify new drug targets,” Liang notes.
Therapeutic implications
The development of these sophisticated organoid models represents a significant
advance in the field of neurological disease research. The ability to observe disease processes in a controlled environment that closely mimics human brain tissue provides researchers with unprecedented opportunities to:
The models enable real-time observation of disease progression, facilitating the development and testing of targeted therapeutic interventions. They also provide a platform for investigating personalised treatment approaches, considering individual genetic variations in mitochondrial function.
While the current research focuses primarily on understanding basic disease mechanisms, the implications for therapeutic development are substantial. The ability to study cellular responses in a complex, three-dimensional model system offers new possibilities for drug development and testing.
The research demonstrates the potential of organoid technology in bridging the gap between basic scientific understanding and clinical applications. As these models continue to be refined, they may provide increasingly valuable insights into the mechanisms underlying various neurological conditions.
Reference: Liang, K. X., et al. (2024). Hallmark Molecular and Pathological Features of POLG Disease are Recapitulated in Cerebral Organoids. Advanced Science https://doi.org/10.1002/advs.202307136
Kristina Xiao Liang, Group Leader of the Mitochondrial Stem Cell Research Group at the University of Bergen.
Nuclear receptor shows promise in diabetic heart disease treatment
A new study reveals that activating the nuclear receptor PPARβ/δ could offer therapeutic potential for diabetic cardiomyopathy, a severe cardiac condition affecting both type 1 and type 2 diabetes patients, which currently lacks specific treatment options.
Identifying the therapeutic pathway
Research published in the November 2024 issue of Pharmacological Research has identified a promising molecular target for treating diabetic cardiomyopathy. The study, led by researchers at the University of Barcelona, demonstrates that activation of the nuclear receptor PPARβ/δ may help counteract the inflammatory and fibrotic processes characteristic of this cardiac condition.
Diabetic cardiomyopathy represents a significant health burden, particularly as it develops insidiously and cannot be directly attributed to hypertension or other cardiovascular disorders. The condition is characterised by complex pathological processes including metabolic alterations, inflammation, fibrosis, and cardiac cell death through apoptosis.
The research team found that the PPARβ/δ receptor, which is particularly abundant in metabolically active tissues, can potentially mitigate disease progression. “Many of the PPARβ/δ-regulated genes are involved in lipid and glucose metabolism. This protein is linked to metabolic diseases with an inflammatory background,” explains Professor Manuel Vázquez-Carrera, one of the study’s lead researchers.
Molecular mechanisms unveiled In diabetic conditions, insulin resistance in the myocardium forces the heart to rely almost exclusively on fatty acid oxidation for energy production. This metabolic shift leads to lipid accumulation and subsequent lipotoxicity, increasing the heart’s oxygen demands. The combination of diabetic hyperglycaemia and lipo-
toxicity triggers inflammatory and fibrotic responses through the activation of specific transcription factors.
Professor Xavier Palomer, co-lead researcher, explains: “Together, all these processes lead to extracellular cardiac remodelling, contractile dysfunction, left ventricular hypertrophy and dilated cardiomyopathy, ultimately leading to heart failure.”
Clinical implications and future directions
The study’s findings are particularly relevant given recent developments in PPARβ/δ-targeted therapeutics. In August 2024, the US FDA approved seladelpar, a selective PPARβ/δ agonist, for treating primary biliary cholangitis. This regulatory milestone could accelerate interest in developing similar compounds for diabetic cardiomyopathy.
The research reveals that PPARβ/δ’s beneficial effects in diabetic cardiomyopathy stem from its ability to inhibit the
MAPK pathway, as demonstrated in cultured human cardiac cells. This mechanism appears to be crucial in preventing inflammation and fibrosis not only in cardiac tissue but potentially in other organs affected by similar pathological conditions.
Therapeutic potential
The study’s findings suggest that pharmaceutical companies might increasingly focus on developing PPARβ/δ-targeted drugs for diabetic cardiomyopathy treatment. This development is particularly significant given the current lack of specific therapeutic options for this serious cardiac condition.
The research team included collaborators from BCNatal, Hospital ClínicIDIBAPS, the University of Cantabria, Marqués de Valdecilla University Hospital, and the University of Lausanne, representing a comprehensive international effort to address this challenging medical condition.
Reference: Rostami, A., Palomer, X., et al. (2024). PPARβ/δ prevents inflammation and fibrosis during diabetic cardiomyopathy. Pharmacological Research https://doi.org/10.1016/j.phrs.2024.107515
Ultrasound-guided biodegradable microrobots used for targeted drug delivery
Novel microrobots constructed from biodegradable hydrogel demonstrate stable propulsion in biological fluids and potential for precision drug delivery, according to research published 11 December 2024 in Science Robotics.
A team of scientists has developed a new class of biodegradable microrobots that can be guided through living tissue using ultrasound and magnetic fields. These bioresorbable acoustic microrobots (BAMs) represent an advancement in addressing key challenges that have limited the practical application of microrobots in medicine, particularly regarding stability and control in biological environments.
The spherical microrobots, constructed using two-photon polymerisation, feature an innovative dual-opening cavity design that enables them to trap gas bubbles more effectively than previous single-opening designs. This structural improvement provides enhanced propulsion stability and speed when the devices are stimulated by ultrasound waves.
Surface chemistry innovations
A significant feature of the BAMs is their carefully engineered surface chemistry. The researchers developed a dual-surface approach, combining a hydrophobic interior with a hydrophilic exterior. This design
serves multiple purposes: the water-repelling inner surface helps maintain trapped gas bubbles essential for acoustic propulsion, while the water-attracting outer surface prevents unwanted aggregation of the microrobots and facilitates their eventual biodegradation.
Navigation and imaging capabilities
The research team demonstrated that BAMs could be tracked in real-time using ultrasound imaging, owing to the acoustic properties of their trapped gas bubbles. This visibility allows for precise control of the microrobots’ movement through tissues. Additionally, the incorporation of magnetic nanoparticles into the hydrogel matrix enables steering using external magnetic fields, providing an additional layer of control.
The microrobots showed impressive versatility in their ability to navigate through various biological fluids, including blood, urine, and gastrointestinal fluid. Notably, they maintained functional stability for several days while gradually biodegrading without producing toxic effects.
Cancer treatment potential
In what may be one of the most promising applications, the researchers tested BAMs loaded with anticancer drugs in mice with bladder tumours. The microrobots successfully maintained their position within the bladder and delivered their therapeutic payload, resulting in significant tumour size reduction over a two-week period.
As noted by Han et al. in the research paper: “These devices demonstrate the potential to shift paradigms in disease diagnosis, targeted drug delivery, and minimally invasive surgery.”
Future implications
The development of these microrobots represents a significant step toward addressing several persistent challenges in minimally invasive medicine. Their ability to combine stable propulsion, real-time imaging capabilities, and controlled drug delivery, while being fully biodegradable, offers potential applications across a range of medical procedures.
Reference:
Han H., et al. Imaging-guided bioresorbable acoustic hydrogel microrobots. Science Robotics, 11 Dec 2024. https://doi.org/10.1126/scirobotics.adp3593
Digital workplace triggers mental health crisis as ‘techno-strain’ grips modern workforce
New research from the University of Nottingham demonstrates significant psychological and physiological impacts of digital technology intensity in modern workplaces, with implications for occupational health.
Understanding the burden
The digital transformation of workplaces, accelerated by the pandemic, has created an environment of persistent connectivity that is generating measurable strain on employees’ wellbeing. A qualitative study published 17 December 2024 in Frontiers in Organizational Psychology [1] reveals that workers are experiencing what researchers term ‘techno-strain’ – a combination of mental and physical stress responses to digital hyperconnectivity.
Researchers from the University’s Schools of Psychology and Medicine conducted indepth interviews with fourteen profession-
als across various sectors. The investigation, which forms the final component of a broader research programme examining digital workplace impacts, identified several key stressors including message proliferation, application overload, and continuous meeting demands. Psychological impact patterns
The study revealed a pervasive pattern of psychological burden associated with digital workplace technology intensity. Participants consistently reported experiencing cognitive overload and affective strain, particularly related to the perceived obligation for constant availability. One participant highlighted this pressure, noting: “You kind
of feel like you have to be there all the time. You have to be a little green light.”
Work-life boundary erosion
A significant finding emerged regarding the dissolution of traditional work-life boundaries in the digital environment. The research documented how the ubiquitous nature of digital workplace tools has created unprecedented challenges for psychological detachment from work. As one study participant explained: “[It’s] just more difficult to leave it behind when it’s all online and you can kind of jump on and do work at any time of the day or night.”
Theoretical implications
The research extends existing Job Demands-Resources literature by introducing and defining the concept of digital workplace technology intensity. Professor Alexa Spence from the School of Psychology emphasises that this construct provides “new insight on the causes of technostress in the digital workplace,” while highlighting both mental and physical health implications.
Mitigation
strategies
The researchers propose several evidence-based interventions for organisations to address these challenges. These include enhancing workers’ digital competencies, implementing boundary management protocols, and optimising digital workplace usability. The findings suggest that technology departments should consider streamlining application proliferation and prioritising user-centred design principles.
Lead researcher Elizabeth Marsh, an ESRC PhD student, emphasises the importance of recognising both benefits and potential hazards of digital workplaces. The study, funded by ESRC-MGS (Economic and Social Research CouncilMidland Graduate School), advocates for continued research into identifying and mitigating digital workplace demands to protect worker wellbeing.
Reference:
Marsh, E., et al. (2024). Being digitally hyperconnected causes ‘techno-strain’ for employees. Frontiers in Organizational Psychology https://doi.org/10.3389/forgp.2024.1392997
AI tool analyses placental photos to speed detection of maternal and neonatal problems
Novel approach to placental assessment
A newly developed artificial intelligence system that analyses photographs of placentas immediately after birth could help clinicians quickly identify infections and other complications, potentially improving care for mothers and newborns, particularly in resource-limited settings. and child health during pregnancy, it is often not thoroughly examined at birth, especially in areas with limited medical resources. Currently, only about 20% of placentas undergo pathology examination in the United States.
Researchers from Northwestern Medicine and Penn State have developed an AI tool called PlacentaCLIP+ that can analyse simple photographs of placentas to detect abnormalities associated with infection and neonatal sepsis, a lifethreatening condition affecting millions of newborns globally.
The study, published in the journal Patterns on 13 December 2024, describes how the system uses computer vision and artificial intelligence to examine placental features that could indicate potential complications requiring immediate intervention.
“Placenta is one of the most common specimens that we see in the lab,” said study co-author Dr Jeffery Goldstein, director of perinatal pathology at Northwestern University Feinberg School of Medicine. “When the neonatal intensive care unit is treating a sick kid, even a few minutes can make a difference in medical decision making. With a diagnosis from these photographs, we can have an answer days earlier than we would in our normal process.”
Bridging the resource gap
The researchers note that while the placenta plays a vital role in maternal
The authors write in their paper that “enhancing the accessibility of placental assessment to pathologists, clinicians, and researchers is crucial. Immediate placental assessment at birth is expected to significantly aid clinical decisions.”
Technical innovation
The system employs cross-modal contrastive learning, an AI method that helps align and understand relationships between visual data (images) and textual data (pathological reports). The researchers trained the model using a large dataset of placental images and pathology reports spanning 12 years.
The resulting system, PlacentaCLIP+, demonstrated an average accuracy rate of over 82% in both internal and external validations, showing promise for widespread clinical applicability.
Real-world applications
The researchers envision the tool being integrated into a user-friendly mobile app that medical professionals could use with mini-
mal training. In well-resourced hospitals, it could help determine which placentas need detailed examination, while in lowresource areas without pathology labs or specialists, it could help doctors quickly identify potential complications.
“This research could save lives and improve health outcomes,” said lead author Yimu Pan from Penn State’s College of Information Sciences and Technology. “It could make placental examination more accessible, benefitting research and care for future pregnancies, especially for mothers and babies at higher risk of complications.”
Future developments
The research team is now working on developing a mobile app version of the tool that could be used by medical professionals in various clinical settings. They plan to make the system even more comprehensive by including additional types of placental features and incorporating more clinical data to improve predictions.
The authors conclude that the system “has the potential to transform neonatal and maternal care by enabling early, personalised interventions that prevent severe health outcomes and improve the lives of mothers and infants worldwide.”
Reference: Pan, Y., Mehta, M., Goldstein, J. A., et. al. (13 December 2024). Cross-modal contrastive learning for unified placenta analysis using photographs. Patterns, 5(101097). https://doi.org/10.1016/j.patter.2024.101097
Innovative tricuspid valve repair without surgery Royal Brompton and Harefield Hospital
At London’s Royal Brompton and Harefield hospital, part of Guy’s and St Thomas’ NHS Foundation Trust, patients can benefit from novel minimally invasive procedures that can repair tricuspid valve regurgitation and avoid the need for open-heart surgery.
The new minimally invasive transcatheter approach targets treatment directly to where it is needed and offers significant improvements to quality of life in patients where surgery is not possible.
Tricuspid valve regurgitation consequences
Dr Robert Smith, a leading consultant interventional cardiologist based at Royal Brompton and Harefield hospitals explains, “Despite being historically overlooked, the tricuspid valve is crucial to heart health, and severe cases of tricuspid regurgitation are associated with significant mortality.”
It’s thought tricuspid regurgitation affects more than 70 million people worldwide and may be due to various factors including age and atrial fibrillation (AF).
At an early stage, symptoms can be mild; but, as the condition worsens, patients may experience breathlessness, fatigue and swell ing of the ankles and legs and, rarely, the ab domen. While diuretic medication may alle viate some symptoms, only reparative surgery can properly restore valve function. As this involves open heart surgery, it’s usually only performed while the patient is having an operation for another heart condition.
Two types of low-risk non-surgical intervention
tients,” explains Dr Smith.
“The first is transcatheter edge-to-edge repair (TEER) where a clip is used to reduce the leak. The second is transcatheter tricuspid valve replacement (TTVR), a newer procedure where the valve is replaced, and the leak is obliterated.” Both procedures are low-risk and take around two hours.
A minimally invasive non-surgical treatment is now being used and could be a game-changer for patients with tricuspid valve regurgitation, particularly those who are too high-risk for open-heart tricuspid valve repair because they are older, have additional health issues or have advanced heart failure.
The procedure is performed with a catheter which delivers direct treatment to the heart via a small incision in the groin.
“There are two treatments available to pa-
Tricuspid valve regurgitation procedure recovery
After a few days of monitoring, the patient is usually able to go home. “One of our patients – who was elderly, frail and possibly facing a palliative care pathway – had the TEER procedure and, a month later, was enjoying regular hobbies,” Dr Smith explains. “There’s no doubt it can make a real difference to people’s lives.”
• Find out more at guysandstthomasspecialistcare.co.uk
Weill Cornell Medicine-Qatar
The health risks of a sedentary lifestyle
Middle East Health speaks to Dr. Robert Ojiambo, Ph.D., Associate Professor of Physiology and Biophysics, Weill Cornell Medicine-Qatar about the health risks associated with a sedentary lifestyle.
Can you describe sedentary behavior and elaborate on why it is considered an independent predictor of adverse health outcomes?
Sedentary behavior is any waking behavior spent in a sitting position or supine. Scientifically, it is defined as energy expenditure that is less than 1.5 metabolic equivalent tasks (METS). This results in the conservation of metabolic energy, which can then be used to fuel pathophysiological processes. There is existing evidence that if you spend time in sedentary behavior, you are conserving energy, and this conserved energy has negative health implications.
What are the primary cardiovascular risks associated with prolonged sitting?
Engaging in 150 minutes of moderate to vigorous physical activity (MVPA) per week protects against adverse cardiovascular (CVD) outcomes such as atrial fibrillation, myocardial infarction, heart failure, and cardiovascular mortality. A large study of 17,000 Canadian adults followed over 12 years showed a significant dose-response relationship between sitting time and cardiovascular mortality. In addition, an Australian study of 8,800 people found that individuals spending over four hours a day in screen-based activity, for instance, watching television, experienced up to 80% increased risk of cardiovascular mortality. A more recent study based on the UK Biobank examined a large sample of about 89,000 individuals over 8 years. It showed that even for individuals who meet the physical activity guidelines, engaging in more than 10 hours of sedentary behavior per day was associated with an increased risk of heart failure and cardiovascular mortality. That means even those
who met the recommended physical activ ity guidelines were still exposed to some level of cardiovascular risk.
How does energy allocation to metabolic processes during sedentary behavior con tribute to harmful health signals?
Current evidence supports the theory that human energy expenditure is constrained. All humans have an upper limit of sustain able energy expenditure levels. Total energy expenditure comprises basal energy expendi ture (energy spent to maintain physiological processes) and activity energy expenditure (energy spent to support physical activity). It is worth noting that sedentary and active individuals tend to have similar total energy expenditure values.
Given that total energy expenditure is constrained (has an upper limit), it follows that for highly active individuals, energy will have to be reallocated from basal en ergy expenditure to support the high de mands of physical activity. On the other hand, sedentary individuals have higher basal energy expenditure (reallocated from the unspent physical activity energy ex penditure). Put differently, sedentary indi viduals have higher Basal Metabolic Rates (BMR) than active individuals. This high BMR is harmful because it is associated with cardiovascular disorders such as Type II Diabetes and correlates with increased visceral adiposity, chronic inflammation, and higher levels of circulating stress hor mones – cortisol, adrenaline, and other dysregulated metabolic processes that are detrimental to health, resulting in poor cardiovascular outcomes. There is a clear pathophysiological connection in that when you have excess basal energy (higher BMR), it supports chronic inflammation and increased hormonal production,
when approaching this threshold, thus acting as an effective population intervention strategy to reduce sedentary time.
With prolonged occupational sitting being unavoidable in many modern workplaces, how can workplaces reduce health effects? There is already some evidence that re-
Dr. Robert Ojambo
ducing sedentary time by just 30 minutes and reallocating this time to moderate to vigorous physical activity can have health benefits.
Providing active workstations such as standing desks to promote working in an upstanding position can help minimize sitting. In addition, a cultural shift to allow standing during formal meetings, intelligent office designs with walking pads, intermittent exercise snacks (less than one-minute bouts of exercise to interrupt prolonged sitting), and office gyms allow one to be physically active in the workplace and minimize toxic sitting. Moreover, offices can encourage physical activity by placing office equipment at a distance from the desk, for instance, a printer where one must stand up and walk to the printer.
In Qatar, strategies are in place to encourage people to move more, such as large, air-conditioned shopping malls, pedestrian walkways, parks, and souqs that provide opportunities to move and intuitively encourage ambulatory behavior.
There are also several innovative community initiatives to promote physical activity and healthy behavior at Weill Cornell Medicine-Qatar (WCM-Q) that fall under the Division of Continuing Professional Development (CPD), the Institute for Population Health (IPH), and Sahtak Awalan – Your Health First, WCM-Q’s flagship public health campaign. In addition, the intelligent building design at WCM-Q encourages movement across offices, lecture halls, labs, classrooms, and theatres.
How does urban living worsen sedentary behavior, and what is the cumulative impact of a sedentary lifestyle across work, commute, and leisure activities?
The conveniences of modern living promote sedentary lifestyles – screen-based entertainment, passive commute, and extensive use of labor-saving devices cumulatively spare energy. Deliberate effort is required to spend energy, and any opportunity at work or home should be used. There is a difference between physical activity and exercise. Exercise is planned and structured, like going to the gym. On the
other hand, physical activity is spontaneous and natural. Running on a treadmill for 30 minutes is unnatural; walking to the mall to buy groceries is natural and doesn’t feel like work. The built environment design in urban areas has an impact on the population’s physical activity levels, and therefore, ecological designs should promote physical activity and minimize sedentary behavior.
Are there any ongoing studies or promising developments in this field?
Current studies in global cohorts are examining the energy demands of modern living and will shed light on energy balance and health. Currently, I am involved in a multinational initiative by the International Atomic Energy Agency (Total Energy Expenditure Across the Lifecourse), where we are looking at the energy demands of modern living and studying energy expenditures in China, Africa, Brazil, and other countries. Since the world is facing the obesity epidemic, we need to understand whether it is because of an inactive lifestyle or changes in diet.
Additionally, mechanistic studies, such as those examining visceral adiposity, altered mitochondrial function, chronic inflammation, and dysregulated metabolic pathways, are recommended to investigate the relation between sedentary behavior/physical inactivity and CVD pathophysiology.
Studies to quantify thresholds for sedentary time with other clinical endpoints, CVD (ischemic heart disease), and all-
About Dr. Robert Ojiambo
“ “
There is existing evidence that if you spend time in sedentary behavior, you are conserving energy, and this conserved energy has negative health implications.
cause mortality are also needed in the MENA region, as most evidence is in Western populations.
Learn more about combating obesity
To learn more about the clinical application of the concepts discussed in this interview, healthcare professionals can attend the ‘Tackling Obesity: Multidisciplinary Approaches for Comprehensive Care’ symposium. Hosted by the Division of Continuing Professional Development (CPD) at WCM-Q, the seminar will take place on January 25, 2025. Scan the QR code to register.
Dr. Robert Ojiambo joined Weill Cornell Medicine-Qatar (WCM-Q) in July 2024 and currently holds the position of associate professor of physiology and biophysics. His research focuses on human energy balance and the relationship between energy intake, energy expenditure, and health.
Previously, Dr. Ojiambo served as the founding head of the physiology department and the chair of the division of basic medical sciences at the University of Global Health Equity in Rwanda.
Dr. Ojiambo has been actively involved with organizations in this field in Kenya, UK, China, and Austria. His work has been supported by funding from various organizations, including the Chinese Academy of Sciences, Catholic Relief Services, the Harvard University Center for African Studies, the Havey Institute for Global Health, and the International Atomic Energy Agency.
Breaking Barriers in Brain Health: A New Era of Advanced Care
The Brain and Performance Centre, a DP World company, leads advancements in brain health through Hyperbaric Oxygen Therapy (HBOT) and holistic, personalised care. Our programmes address neurological and cognitive conditions by integrating physical, cognitive, and nutritional therapies tailored to each patient.
HBOT treatments utilize state-of-the-art hyperbaric chambers to deliver oxygen at high pressures, enhancing neuroplasticity, reducing inflammation, and accelerating natural healing processes. These therapies, combined with comprehensive bespoke care plans, empower patients to achieve optimal recovery and long-term wellness.
Our work in addressing Traumatic Brain Injury (TBI), stroke, and Long COVID, transforms lives while contributing to the region’s public health by bringing people back to being productive members of society.
Mild Cognitive Impairment and Preventing Dementia
Mild Cognitive Impairment (MCI) represents a critical stage where early intervention can significantly impact outcomes. Left untreated, MCI often progresses to dementia, a debilitating condition.
Our HBOT protocols enhance brain oxygenation, create new blood vessels, and improve neuroplasticity. These therapies, supported by cognitive training and nutritional interventions, help patients maintain mental clarity and independence. By advocating for early detection, we aim to prevent cognitive decline before it becomes irreversible.
Traumatic Brain Injury: Breaking New Ground TBI remains a complex condition, with effects ranging from mild post-concussion symptoms to severe disabilities. Our tailored
approach integrates HBOT as a cornerstone of care, promoting cellular rehabilitation, enhanced neuroplasticity, reduction of inflammation, and accelerated brain healing.
For young patients with Post-Concussion Syndrome (PCS), early intervention through HBOT addresses immediate symptoms and fosters long-term resilience. This innovative programme underscores our dedication to advancing paediatric brain health.
Cerebral Palsy: Nurturing Potential
Children with Cerebral Palsy (CP) face significant physical and neurological challenges. Our multidisciplinary approach combines HBOT with customised physical and occupational therapy, alongside nutritional interventions, to address their unique needs.
By treating the core cause of disability, the brain tissue, HBOT enables the enhancement of neuroplasticity and motor functions, this fosters new opportunities for growth and independence. In addition to our empiric pre and post treatment testing, parents frequently report improvements in movement, speech, and overall daily independence achieved by combining HBOT and vigorous rehabilitation training.
Stroke Recovery: A Comprehensive Approach
Stroke is a leading cause of disability, and traditional rehabilitation often falls short of achieving the stroke survivors’ full rehabilitation potential. Our stroke rehabilitation programme combines HBOT with physical, cognitive, and nutritional therapies, to promote recovery from the cellular to the functional level, encouraging neuronal regeneration, improving cognitive and physical performance, and reducing the long-term effects of ischaemic damage.
In recent years, studies have been published, highlighting the significance of HBOT as a powerful tool to gain improvements in patients’ mobility, memory, and overall quality of life following stroke recovery, demonstrating the power of combining innovative treatments with compassionate care.
Long COVID: A New Frontier
Long COVID has emerged as a significant healthcare challenge, with symptoms such as fatigue, brain fog, and respiratory issues continuing for months after recovering from the initial infection. Our HBOT programme targets systemic inflammation and enhances oxygen delivery to the damaged tissues, thus, treating the root causes of the post-viral symptoms.
By utilizing our enhanced HBOT protocol and creating bespoke holistic care plans, we have helped patients regain their precovid levels of physical and cognitive performance, enabling them to return to being fully functional at work and with their families. Supported by cutting-edge research, our centre serves as a beacon of hope for individuals affected by this condition.
A Vision for the Future
The Middle East has long been a hub of innovation in healthcare. Looking ahead, it is crucial to invest in advanced medical research and holistic treatment approaches. By targeting conditions such as: TBI, stroke, and Long COVID. With cutting-edge solutions, we are transforming lives and strengthening the regional health resilience.
At The Brain and Performance Centre, we are committed to pushing the boundaries of brain health. Our mission is not only to heal but to empower patients to live life to the fullest.
By Dr. Semer Wang, Medical Director at The Brain & Performance Centre
The Ohio State University Comprehensive Cancer Center –James Cancer Hospital and Solove Research Institute
Committed to creating a cancer-free world
The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James https://cancer.osu.edu) is dedicated to creating a cancer-free world by integrating scientific research with excellence in education and patient-centered care – a strategy that leads to better methods of prevention, detection and treatment.
Ohio State has been designated a National Cancer Institute (NCI) Comprehensive Cancer Center for nearly 50 years and is one of only a few centers funded by the NCI to conduct phase I, II and III clinical trials on novel anticancer drugs provided by the NCI. In its last three formal reviews for five-year re-designation, the university’s cancer program, embodied in the OSUCCC – James, has received the NCI’s highest descriptor of “exceptional.”
The OSUCCC – James has $140 million in active cancer-relevant research funding, and over $76 million of that total – more than half – comes from the NCI. In 2023 alone, Ohio State cancer researchers received 46 new research grants from the NCI.
Cancer research
The OSUCCC – James has over 320 full or introductory cancer researchers who collectively represent 12 of the 15 colleges at Ohio State. Each researcher is a member of one of five multidisciplinary research programs: Cancer Control; Leukemia and Hematologic Malignancies; Cancer Biology; Molecular Carcinogenesis and Chemoprevention; or Translational Therapeutics. In 2023, these researchers authored or co-authored 941 publications in peer-reviewed journals. In addition, OSUCCC – James researchers opened 140 clinical trials in 2023, bringing the total number of cancer clinical trials at Ohio State to approximately 650. These studies offer the latest cancer treatments, some of which are available nowhere else.
As the cancer program’s 356-bed adult patient-care component, The James is the
third-largest cancer hospital in the United States and one of the top cancer hospitals in the nation as ranked by U.S. News & World Report. With 21 floors and more than 1.1 million square feet, The James is a transformational facility that fosters collaboration and integration of cancer research and clinical care. Because early diagnosis is the key to successful cancer treatment, The James Cancer Diagnostic Center at the OSUCCC – James provides patients who may have cancer with direct, expedited access to diagnostic testing.
The OSUCCC – James since 2014 has enrolled nearly 70,000 patients in a Total Cancer Care® (TCC) protocol for voluntarily sharing de-identified clinical data that advances cancer research and personalizes cancer care. The TCC protocol has been adopted by all 19 member institutions across the United States that constitute the Oncology Research Information Exchange Network (ORIEN), a research collaboration co-founded and co-anchored by the OSUCCC – James and Moffit Cancer Center in Tampa, Florida. Through ORIEN, TCC-consented patients across the United States donate clinical data for research that helps molecular level.
International reputation and global destination
Because of its international reputation for providing outstanding research-based cancer care, the OSUCCC – James is regarded as a global destination of choice, serving patients from all 50 U.S. states, three U.S territories and 90 other countries. The institution’s Destination Medicine Global Health Care team <https://cancer.osu.edu/ destinationmedicine> is dedicated to ensuring that distance and language are no obstacles to receiving the internationally recognized cancer care available at Ohio State.
The human heart can repair itself when given a helping hand
Research reveals that failing hearts have minimal capacity for self-repair, but mechanical support can trigger remarkable regeneration of heart muscle cells, opening new therapeutic possibilities.
Scientists have discovered that whilst the human heart’s ability to repair itself is severely diminished during heart failure, supporting the heart with a mechanical pump can stimulate regeneration of heart muscle cells at rates significantly higher than in healthy hearts. This groundbreaking finding, published recently in the
journal Circulation [1], suggests there may be untapped regenerative potential in diseased hearts that could be therapeutically exploited.
Understanding heart repair
The research team, led by scientists at Karolinska Institutet in Sweden, investigated
the heart’s capacity to generate new cardiac muscle cells (cardiomyocytes) under different conditions. They studied tissue samples from 52 patients with advanced heart failure, including 28 who received support from a left ventricular assist device (LVAD) – a surgically implanted pump that helps propel blood.
Using an innovative method to determine cell age based on radioactive carbon dating, the researchers found that heart failure patients without mechanical support showed extremely low rates of cardiomyocyte renewal – 18 to 50 times lower compared to healthy hearts.
Mechanical support triggers regeneration
However, the results were strikingly different in patients receiving LVAD support whose hearts showed significant improvement. These “responder” patients demonstrated cardiomyocyte renewal rates more than six times higher than those seen in healthy hearts.
“The results suggest that there might be a hidden key to kick-start the heart’s own repair mechanism”, says Olaf Bergmann, senior researcher at the Department of Cell and Molecular Biology at Karolinska Institutet and one of the authors of the paper.
Complex cellular changes
The study revealed complex cellular changes in failing hearts. The researchers found that heart failure patients showed increased DNA synthesis in cardiac cells, but this was primarily related to cells becoming larger (polyploidization) and developing multiple nuclei (multinucleation) rather than generating new cells.
In non-LVAD patients and those who didn’t respond to LVAD therapy, less than 0.3% of DNA synthesis was attributed to actual cell renewal. However, in LVAD responders, nearly 30% of DNA synthesis was linked to the generation of new cardiomyocytes.
Implications for future treatments
These findings have significant implications for developing new heart failure therapies. The research demonstrates that the adult human heart possesses greater
regenerative potential than previously thought, but this capacity appears to be suppressed during heart failure.
The authors note in their paper: “Our data demonstrate that cardiomyocyte renewal is minimal in failing hearts but can elevate well beyond the levels observed in healthy hearts through LVAD-mediated functional cardiac improvement.”
Regenerative mechanism remains unclear
While the discovery is promising, the mechanism behind this regenerative effect remains unknown. As Bergmann notes: “It is difficult to say. In the existing data we cannot find an explanation for the effect, but we will now continue to study this process at a cellular and molecular level.”
The research team acknowledges in their paper that the relationship between functional improvement and cell renewal is complex: “Because of the nature of our study, it is difficult to understand the exact causal relationship between reverse remodelling, functional improvement and cardiomyocyte renewal in the patients studied. However, our results demonstrate that reverse remodelling likely plays an important role in the observed phenotype.”
They also note that most DNA synthesis in failing hearts appears ineffective at generating new cells: “The fact that cardiomyocyte renewal is greatly reduced in heart failure suggests that the increased cardiomyocyte DNA synthesis, as determined by changes in genomic 14C levels in failing hearts, is almost exclusively related to polyploidization and multinucleation.”
Future therapeutic possibilities
The findings point toward potential new treatment approaches. As the authors explain in their discussion: “The discovery
Cardiology
The results suggest that there might be a hidden key to kick-start the heart’s own repair mechanism.
of a latent cardiomyocyte regenerative potential in the adult human heart identifies an attractive target for new therapies. This motivates studies to unveil the molecular regulation of this process, which would facilitate the development of pharmaceutical therapies for heart regeneration.”
The research team suggests that mechanical unloading might work through multiple mechanisms: “For instance, mechanical unloading might reverse metabolic cascades that increase reactive oxygen species production. This, in turn, can reduce oxidative DNA damage and activation of the DNA damage response pathway that causes cell cycle arrest in cardiomyocytes.”
This research opens new avenues for developing treatments that could stimulate the heart’s natural repair mechanisms. Such approaches could potentially reduce reliance on heart transplants or long-term mechanical support devices.
The study suggests that understanding how mechanical unloading triggers cardiac regeneration could lead to new therapeutic strategies. These might focus on creating conditions that promote actual cell renewal rather than just cellular enlargement, potentially offering new hope for heart failure patients.
Reference: Derks, W., Rode, J., Collin, S., et. al. (2024). A latent cardiomyocyte regeneration potential in human heart disease. Circulation. doi: https://doi.org/10.1161/CIRCULATIONAHA.123.067156
Heidelberg University Hospital
Revolutionary Heart Surgery
A new era in artificial heart surgery
The cardiac surgery team at Heidelberg University Hospital has for the first time successfully implanted fully artificial hearts, the Aeson by Carmat, into two patients. Unlike mechanical assist devices that support a failing biological heart, these systems completely replace it. In these cases, the heart muscle no longer pumps blood; instead, a robotic marvel has taken over, with only a power cable emerging from the patients’ abdomens.
Critically ill heart failure patients often face a long wait for donor organs, averaging six months for those in the most urgent categories. For many, this delay is too long. To address this, Heidelberg’s cardiac surgery team implanted the latest generation of CarmatAeson artificial hearts into two patients in 2024. Both patients, aged 51 and 58, have recovered well from their surgeries.
Advanced design mimics the natural heart
The CarmatAeson mimics natural heart function using a hydraulic pump that pro-
duces a pulsating blood flow. Built-in sensors continuously monitor blood pressure and adjust the pumping rate to match the body’s demands. Biomembranes and heart valves made from bovine tissue minimize blood clot formation, reducing the need for strong anticoagulants. The device, slightly larger and three times heavier than a natural heart, is surgically inserted into the chest and stitched to the heart’s major blood vessels and atria. After the chest is closed, a cable exits the abdomen to connect to external batteries carried in a 4-kilogram bag that can be worn as a
Carmat Aeson
backpack or sling. These batteries last six to seven hours and require regular charging. The Carmat heart is approved for six months, but some patients have used it for longer. Of 52 people implanted with the device since 2022, 20 have already received donor hearts.
Prof. Dr. Anna Meyer, head of the transplant and mechanical circulatory support program at Heidelberg University Hospital, explains how the artificial heart works using an X-ray image. It is larger than a normal heart, so before the operation, a 3D reconstruction from the computer tomography data is used to check whether the heart robot fits into the chest.
Patient experiences
The surgeries were highly complex but remarkably successful. Both patients recovered quickly, regaining independence, and showing significant improvements in liver, kidney, and intestinal functions that had deteriorated due to poor circulation from their severe heart failure.
One patient, whose heart function had dropped to just 15% due to an autoimmune condition, described the device as lifechanging: “I don’t feel the artificial heart, though getting used to the noise took a few nights.” He had previously been bedridden for weeks, relying on an external machine to oxygenate his blood. Following the surgery, he began walking with a rollator
and now looks forward to rebuilding his
Whether the device will see broader use depends on how the Heidelberg patients’ progress. The team remains optimistic, noting the rapid recovery and regeneration of other organ systems.
The Department of Cardiac Surgery
at Heidelberg University Hospital
Heidelberg University Hospital, ranked 15th among the World’s Best Hospitals according to the Newsweek 2024 ranking, is renowned for its specialized clinical care across all fields of medicine. Its world-class research and teaching activities ensure continuous progress and the most up-todate patient care.
The Department of Cardiology ranked
19th among the World’s Best Specialized Hospitals in 2025. The Cardiac Surgery is an integral part of the world-renowned Heidelberg Heart Center. Over more than five decades, it has developed a strong focus on minimally invasive adult cardiac procedures, thoracic aortic surgery and pediatric cardiac surgery. The team of cardiologists and surgeons care for patients from all over the world who are looking for the optimal treatment option, whether interventional with catheters or minimally invasive surgery. The team, led by the Medical Director of the Department of Cardiology, Professor Dr. Matthias Karck, performs more than 1,600 major heart surgeries annually. In 2023, 22 heart transplants were carried out, and 135 patients were treated with mechanical heart support systems.
Implantable artificial heart applied for national and international patients
National and international patients in need of complete/partial artificial heart have access to this innovative surgery and could benefit from it. At the department of Cardiac Surgery, a procedure was recently successfully performed on an Egyptian patient, who received a durable left ventricular assist device.
Services for international patients
• Multilingual international team
• Telemedicine
• Certified interpreters
• Support in obtaining a medical visa
Contact Heidelberg University Hospital Medical International Office International.Office@med.uni-heidelberg.de www.heidelberg-university-hospital.com
Prof. Dr. Anna Meyer, MBA
Cardiology
The heart’s hidden brain: Complex neural network controls cardiac rhythm
A groundbreaking study reveals the heart possesses its own ‘mini-brain’ – a sophisticated nervous system that plays a crucial role in cardiac rhythm control, challenging long-held views about heart regulation.
Scientists from Karolinska Institutet and Columbia University have uncovered compelling evidence that the heart’s intrinsic nervous system is far more complex and autonomous than previously understood. Their research, published online 4 December 2024 in Nature Communications [1], demonstrates that the heart contains diverse populations of neurons that function similarly to brain cells in controlling rhythmic activity.
“This ‘little brain’ has a key role in maintaining and controlling the heartbeat, similar to how the brain regulates rhythmic functions such as locomotion and breathing,” explains principal researcher Konstantinos Ampatzis, docent at the Department of Neuroscience, Karolinska Institutet.
Sophisticated neural network
The research team conducted their investigation using zebrafish, which exhibit remarkable similarities to human cardiac function. Through a combination of single-cell RNA sequencing, anatomical studies, and electrophysiological techniques, they mapped out an intricate network of neurons embedded within the heart wall.
The findings revealed several distinct types of neurons, including a particularly significant discovery of neurons with pacemaker properties. These specialised cells displayed characteristics similar to central pattern generator networks found in the brain, suggesting they play a vital role in maintaining cardiac rhythm.
Neurotransmitter systems
The study identified multiple neurotransmitter systems operating within the cardiac neural network. While the majority of neurons (approximately 81%) were cholinergic (acetylcholine-producing), the researchers also found populations of glutamatergic, GABAergic, and serotonergic neurons, indicating a complex system of chemical signalling within the heart.
“Our data argue against the notion that the intracardiac nervous system is a simple parasympathetic postganglionic structure that relays central efferent information,” the authors note in their discussion. “Our single-cell sequencing, anatomical, and physiological datasets revealed several different neuronal types, including sympathetic and parasympathetic neurons and sensory neurons with an apparent neurochemical and functional diversity.”
Analysis of the neuronal activity patterns revealed four distinct types of neurons based on their firing characteristics: single spike, adaptive, repetitive, and bursting types. The bursting neurons demonstrated properties typically associated with pacemaker cells, suggesting their involvement in rhythm generation.
A novel model of cardiac regulation
The researchers propose a novel model of cardiac regulation. As they explain in the paper: “It is conceivable, indeed probable, that the vertebrate heart has a two-layer localized pacemaking/control system, a nodal pacemaker, which exhibits spontaneous depolarization and activity and is responsible
for generating the inherent heart rate, and a neuronal regulatory module that dictates the operational range after integrating and computing central and peripheral information.”
Clinical implications
This newfound understanding of cardiac neural complexity could have significant implications for treating heart conditions. “Understanding this system better could lead to new insights into heart diseases and help develop new treatments for diseases such as arrhythmias,” notes Ampatzis.
The study authors emphasise the broader implications: “Cell-type-specific classifications of intracardiac neurons will facilitate further functional analyses of the diverse but stereotypic neuron populations that generate and gate sensory and motor functions to control the vertebrate heart.”
Future research directions
The team plans to investigate how this cardiac ‘brain’ interacts with the central nervous system under various conditions, including exercise, stress, and disease states. They aim to identify new therapeutic targets by examining how disruptions in the heart’s neuronal network contribute to cardiac disorders.
This work fundamentally challenges the traditional view that the heart’s nervous system merely relays signals from the brain. Instead, it reveals an autonomous network capable of sophisticated information processing and rhythm generation, opening new avenues for cardiac research and therapeutic development.
Reference: Pedroni, A., Yilmaz, E., Ampatzis, K., et. al. Ampatzis, K. (2024). Decoding the molecular, cellular, and functional heterogeneity of zebrafish intracardiac nervous system. Nature Communications, 15(1), 10483. https://doi.org/10.1038/s41467-024-54830-w
Sidra Medicine transforming lives through cardiac excellence
A new standard for cardiac care in the region
The heart is at the center of life, and for families dealing with serious heart conditions, finding the right care can feel overwhelming. We are committed to personalizing and making advanced heart treatments accessible to families across the MENA region and beyond.
Our focus is clear – to give patients the personalized care they need, when they need it most, with compassion and expertise.
Leading in complex heart treatments
Sidra Medicine was established with a clear vision: to deliver specialized healthcare for women, children and young people in the MENA region and providing them with world-class expertise close to home. While our services span various specialties, our Heart Center stands out as a beacon of hope for families facing complex cardiac conditions.
Our team specializes in performing lifesaving surgeries for newborns, such as the Norwood procedure for hypoplastic left heart syndrome (HLHS) and the arterial switch operation for transposition of the great arteries (TGA). We also provide comprehensive care for individuals with congenital heart disease (CHD) using cutting-edge techniques. For valve repairs and replacements, we offer advanced options like the Ross and Ozaki procedures, along with repairs for aortic, mitral, and tricuspid valves. This includes specialized approaches like cone repair for Ebstein malformation. Our team has the largest and most extensive experience in the region with transcatheter pulmonary valve replacement, utilizing valves such as Venus P, Edwards, Medtronic, and MyVal.
Each successful procedure is a step to ward a healthier, more hopeful future for our patients.
A team that works together for better results
One of the things that makes our approach unique is our focus on teamwork and pre cision medicine. Our Heart Center team includes expert cardiac surgeons, inter ventional cardiologists, anaesthesiolo gists, and specialized cardiac nurses. These specialties are particularly effective for patients with complex heart conditions, as they combine the best of surgical, inter ventional, and supportive care.
In addition, our Heart Center team col laborates with other departments, such as imaging specialists, respiratory therapists, and rehabilitation experts, to ensure com prehensive care that enhances recovery and long-term health.
Personalized care close to home
For many families in the region, seeking ad vanced medical care often means traveling far from home, leaving behind support net works and familiar surroundings. We have transformed access to care in the MENA region, bringing world-class, personalized treatments closer to home so families no longer have to seek solutions abroad.
From neonatal surgeries, CHD proce dures to respiratory and cardiac ECMO support, we provide precision health ser vices that match or exceed global stan dards. Families can trust that they are receiving the highest level of care without the added stress of traveling far away.
boundaries and deliver exceptional care, we invite you to trust us with your heart and the hearts of your loved ones.
Dr. Iyabo Tinubu-Karch, CEO, Sidra Medicine
CMC Beirut unveils advanced innovations in cardiovascular imaging
Clemenceau Medical Center, Beirut (CMC) continues to prioritize top-tier healthcare for its patients by equipping its Cardiovascular Imaging Department with cutting-edge technology. These advancements enable precise and prompt diagnosis of heart diseases, assisting physicians in making timely treatment decisions. This commitment solidifies Clemenceau Medical Center’s leadership in accurately diagnosing and treating cardiovascular conditions in Lebanon and the wider region.
The Center’s role is a premier and referral destination for Cardiovascular care. Non-invasive Cardiology has progressively evolved during the past years and undergone significant upgrades, most notably in the field of Cardiac and Vascular Imaging. The Revolution APEX Cardiac CT scan is a state-of-the-art device and among the most advanced globally, and CMC Beirut is proudly the first facility in the Middle East to offer this technology to the patients.
One of the key benefits of this new technology is the substantial reduction in radia-
tion exposure, making the imaging process safer, particularly for patients who require frequent scans. Additionally, advanced technology allows to use less contrast dosage to achieve high-quality images, which is especially beneficial for patients with chronic kidney disease
Advanced CT
The Revolution APEX CT scan also features the Single Beat Acquisition and the Snapshot Freeze Algorithm technology, enabling to capture high-quality images even when a patient’s heart rate is elevated. This is a significant achievement compared with older machines that required an average heart rate of 60 beats per minute to perform good quality images. The advancements in speed and sensitivity in the new machine allow imaging cardiologists to obtain highquality images with a faster heart rate.
Moreover, the Center is now providing FFR-CT (Fractional Flow Reserve CT), the first of its kind in Lebanon and the Middle East. It is a new technology and a
Non-Invasive Cardiology Department at Clemenceau Medical Center, Beirut
new type of non-invasive procedure (no incisions or interventions required) which uses flow analysis to determine whether the heart muscle suffers from ischemia, particularly in cases where the coronary artery blockage is moderate between 50 and 70%. Additionally, the American Heart Association / American College of Cardiology guidelines highlight the use of FFR-
Evelina London Children’s Hospital
World-leading children’s heart care
Evelina London Children’s Hospital, ranked by US Newsweek as one of the world’s best children’s hospitals, is home to our world-leading cardiology and cardiac surgery service. It is also one of only two specialist children’s hospitals in London, and we are proud to have Her Royal Highness The Princess of Wales as our Patron.
As a world-leading centre we provide life-changing care and comprehensive medical and surgical services from before birth to later in life. As part of Guy’s and St Thomas’ NHS Foundation Trust, one of the world’s most prestigious healthcare organisations, we draw on the expertise of multidisciplinary teams to offer high-quality care and clinical excellence.
Evelina London is situated next to St Thomas’ Hospital in central London, in proximity to iconic landmarks like the Houses of Parliament and the London Eye. Its location enables children and their families to conveniently access various clinical services, expertise, and the latest treatments all at one site.
Leading innovation in children’s cardiology and cardiac surgery
We have a long history of innovation and world-firsts, developing cutting-edge technology and making advances to transform care for patients with complex heart disease.
Our cardiology specialists cover numerous areas of expertise, from the fetus to the adult and across both congenital and acquired heart disease, including heart rhythm abnormalities. An area that truly sets Evelina London apart is our cardiac imaging expertise.
Advanced rapid response cardiac imaging
Evelina London has the longest established and largest fetal cardiology service in the UK. In addition to advanced ultrasound techniques, we’ve pioneered a unique fetal cardiac MRI programme to identify cardiovascular problems before birth. In addition to our pioneering 3D fetal cardiac MRI service, our specialists and researchers are also working on virtual reality (VR) imaging to further improve
accuracy in diagnostics and treatment for our young patients.
Dr Miller, Consultant in Paediatric and Fetal Cardiology says: “Our children’s cardiac MRI and 3D echo service has been established for decades. To further develop this clinical excellence, our imaging specialists and clinical academics collaborate within King’s College London (KCL), carrying out world-leading research, to the benefit of all patients at Evelina London.”
Our innovative VR technology brings together multiple scans to build 3D digital heart images, which provide a clearer view of individual characteristics of each patient’s heart which allows our specialists to trial options in VR before performing actual surgery.
To improve detection of congenital heart disease during routine pregnancy scans, our specialists and researchers, working with imaging scientists at KCL, are developing an artificial intelligence (AI) approach to improve the scan accuracy and efficiency. A computer network processes thousands of ultrasound images, with the algorithm learning features to automatically identify anomalies in fetal hearts. Such advances may improve efficiency and accuracy of fetal diagnoses, working closely with established techniques and clinical teams to offer a rapid response diagnostic service to expecting parents.
“Our whole cardiology group is very strong in cardiac imaging,” explains Dr Miller. “Advances in the world of cardiac imaging can shorten patient waiting times and reduce the need for multiple surgeries, resulting in better outcomes for patients and their families.”
We know how stressful an undiagnosed cardiac issue can be both for our young patients and their families. Our paediatric cardiologists offer a streamlined diagnostic process with the aim of examining the child, carrying out initial tests and interpreting results, providing a diagnosis and counselling the parents, usually all within a single appointment. This is available to all patients including international referrals.
Complex cardiac surgery
The latest addition to our team is Professor David Barron, who brings with him de-
cades of experience in cardiac surgery and educational leadership.
Professor Barron will join Evelina London in early 2025 as the new Chief of Congenital Cardiac Surgery, leading the combined cardiac surgical programme at Evelina London and Royal Brompton Hospital.
Professor Barron has been Division Head at The Hospital for Sick Children (SickKids), Toronto and Professor of Surgery at the University of Toronto, which is in the top 5 surgical programmes in North America, steering SickKids to the highest quality outcomes in its history. Previously, Professor Barron was the Senior Cardiac Surgeon at Birmingham Children’s Hospital, where he had been a consultant surgeon since 1999.
Professor Barron graduated from St Thomas’ Hospital with postgraduate cardiothoracic surgical training at Papworth Hospital, Royal Brompton and Great Ormond Street. He is dual qualified in internal medicine and cardiothoracic surgery and has a doctorate (MD) from in biomechanical assist. He has been national lead for UK Congenital Cardiac Training and has been on the Executive of the British and European Cardiothoracic Societies.
Professor Barron’s research has focused on surgical innovations and 3D printing for complex heart conditions including hypoplastic left heart, complex pulmonary atresia and congenitally corrected transposition.
Expert joined-up care
Our multidisciplinary team of specialists offer an extensive range of congenital cardiac surgeries, including newer techniques
Professor David Barron, new Chief of Cardiac Surgery at Evelina London
for highly complex congenital heart problems for both single ventricle palliation and for complex biventricular corrective surgery, all with excellent outcomes.
Our hospital continues to grow, including our new cardiac and critical care unit
which offers the latest technology, private bays and a spacious, modern, welcoming environment. Our surgical expertise combined with support from leading experts and intensive care facilities, enables us to provide complete care, even for the most
Recognised as one of the world’s best children’s hospitals – US Newsweek for 2025
complex patients, all in one place.
• Contact us to find out more about our specialist services:
Tel: +44 (0)20 7188 5197
Email: privatepatientenquiries@gstt.nhs.uk
Web: www.guysandstthomasspecialistcare.co.uk
Mayo Clinic
Hourglass-shaped stent could ease severe chest pain from microvascular disease
A study at Mayo Clinic suggests that an hourglass-shaped stent could improve blood flow and ease severe and reoccurring chest pain in people with microvascular disease. Of 30 participants in a phase 2 clinical trial, 76% saw improvement in their day-to-day life. For example, some participants who reported not being able to walk around the block or up a flight of stairs without chest pain were able to do these ordinary physical activities at the end of a 120-day period. Clinical measures of blood flow related to the microvasculature of the heart significantly improved during follow-up, according to findings published in the Journal of the American College of Cardiology: Cardiovascular Interventions.
Microvascular disease is a condition in which tiny blood vessels in the heart are not working properly, resulting in reduced blood flow to the heart. The resulting chest pains, or angina, can be debilitating, limiting a person’s ability to exercise, do household chores or even walk to the mailbox. About 40% of patients receiving a diagnostic coronary angiogram for chest pain do not have blocked arteries that also can cause angina. However, up to 66% of these patients do have coronary microvascular disease, which is more common in women overall and found in people with conditions such as diabetes, high blood pressure and obesity.
For decades, there have been few viable treatment options to improve blood flow through the tiny vessels of the heart. At most, doctors have treated symptoms of angina with several medications and cardiovascular disease prevention methods, including healthy eating, weight loss and regular exercise. The use of a stent could
target the issue behind the chest pain – the severe reduction in blood flow affecting the heart muscle.
Unlike tube-shaped stents used to open clogged arteries, the hourglass-shaped stent narrows in the middle. The different design is thought to increase back pres sure, redistributing blood flow more fully through small vessels in the heart that were not working at capacity.
“The patients with heart-related micro vascular dysfunction in this study had lit tle ability to control their chronic angina, which severely limited their day-to-day activities,” says Amir Lerman, M.D., a cardiologist at Mayo Clinic and senior au thor of the study. “Beyond reductions in chest pain and being able to comfortably handle more physical activity, the major ity of patients in the study also showed a connection between the changes in their coronary flow reserve, which is a measure of maximum blood flow, and changes in their quality-of-life responses on the survey. This points to the link between the physiological measurement and angina symptoms.”
Dr. Lerman notes that more studies are needed to better understand how the reducer stent works and its long-term effects on blood flow. The stent did not improve chest pain symptoms in 20%-30% of the participants, so future research studies will need to better identify which patients respond best to this therapy.
For more than a hundred years, people from all walks of life have found answers at Mayo Clinic. In fact, more than one million patients from nearly 130 countries travel to Mayo Clinic locations each year for medical care. Mayo Clinic locations in the United States include Rochester,
Minnesota; Scottsdale and Phoenix, Arizona and Jacksonville, Florida. As a global organization, we also welcome and care for patients at Mayo Clinic Healthcare in London, United Kingdom.
To find out how you can collaborate with Mayo Clinic or to refer a patient, visit: mayoclinic.org or can the QR code.
King Faisal Specialist Hospital & Research Centre
From pioneering robotic surgeries to world-class oncology treatments, KFSHRC is shaping the future of medical tourism in Saudi Arabia
Catering to international patients with personalized plans and seamless journeys, KFSHRC breaks down barriers to advanced medical services.
In our increasingly connected world, healthcare is becoming more sophisticated every day. Innovations are emerging in every medical field at an immensely rapid pace – too fast to track. Yet, despite the unprecedented progress, patients seeking advanced medical solutions still encounter fragmented healthcare systems and limited access to advanced treatments far too often.
Institutions like King Faisal Specialist Hospital & Research Centre (KFSHRC) are working to bridge these gaps with a patient-centric approach, which is underpinned by innovation.
KFSHRC has earned its reputation as a premier destination for international patients through its specialized Centres of Excellence, which combine decades of expertise with prestigious accreditations like JCI and ANCC. Specializing in cardiology, oncology, neurosciences, organ transplantation, and medical genetics, these centres tackle complex challenges with cutting-edge treatments. The Oncology Centre serves international patients, offering novel therapies such as CAR T-cell treatments and advanced radiation techniques.
KFSHRC has also been recognised for its ability to deliver life-saving care and hope to patients who have exhausted conventional treatment. Landmark achievements include the world’s first fully robotic heart & liver transplants.
Advancing modern medicine
Thanks to thousands of robotic-assisted surgical procedures, survival rates exceed global benchmarks, highlighting the hospital’s commitment to advancing modern medicine.
The International Healthcare Services Office at KFSHRC provides seamless care for international patients. By offering personalized treatment plans, coordinating appointments, and facilitating visa processes, the office makes it easier for patients to access advanced medical services. ensuring international patients
recovery within a supportive and integrated environment.
As Saudi Arabia transitions from a top source of outbound medical tourism to a global hub for specialised care, KFSHRC stands at the heart of this transformation. In 2023, KFSHRC generated over 125 million SAR in revenue from international patients, demonstrating its growing appeal to patients worldwide.
KFSHRC’s comprehensive patient journey begins with initial medical consultations and extends to post-treatment evaluations and follow-ups. The Patient Journey Map enhances this standard of service, ensuring a seamless and personalized experience at every stage. This innovative approach enhances patient satisfaction and outcomes, reflecting KFSHRC’s dedication to excellence.
Accessibility is another key factor. With locations in Riyadh, Jeddah, and Madinah, KFSHRC is well-positioned to serve patients from the GCC, South Asia, and beyond. Its proximity to cultural and religious landmarks, such as the holy cities of Mecca, Medina, and Al-Ula, is also advantageous to many patients. By 2024, the hospital had treated patients from 17 countries, with 77% coming from neighbouring GCC nations.
KFSHRC remains committed to innovation, excellence, and accessibility. Its slogan, “WorldClass Care Beyond Borders,” reflects its mission to extend medical innovation globally through its compassionate and specialized care model.
At Arab Health 2025, KFSHRC braces for more achievements and heightened international collaboration that will broaden its global impact. By expanding services, strengthening partnerships, and focusing on patient-centric solutions, KFSHRC aspires to shape the future of medical tourism while reinforcing its international standing. It invites patients and global healthcare leaders to join its mission of transforming lives by advancing the quality of care and – most importantly – ensuring it is accessible to all.
KFSHRC has achieved remarkable recognition by being ranked first in the Middle East and Africa and 20th globally on the list of the world’s top 250 Academic Medical Centres for the second consecutive year. It has also been named the most valuable healthcare brand in both the Kingdom and the Middle East, according to the 2024 Brand Finance rankings. Furthermore, in the same year, KFSHRC was recognized among the world’s best 250 hospitals and was included in the World’s Best Smart Hospitals list for 2025 by Newsweek magazine.
For more information, please visit: www.kfshrc.edu.sa or contact our media team at: mediacoverage@kfshrc.edu.sa.
Faecal microbiota transplantation shows promise for diabetic gastroenteropathy
A randomised controlled trial demonstrates significant improvements in gastrointestinal symptoms and quality of life for type 1 diabetes patients receiving faecal microbiota transplantation, offering potential relief for a traditionally difficult-to-treat condition.
Treatment efficacy
The Danish study, conducted at Aarhus University Hospital, investigated the effectiveness of faecal microbiota transplantation (FMT) in treating diabetic gastroenteropathy, a condition affecting up to 25% of individuals with type 1 diabetes. The trial included 20 patients who were randomly assigned to receive either FMT capsules or placebo, with all participants receiving active treatment after four weeks.
Measurable improvements
Results showed marked symptom reduction in the treatment group, with Gastrointestinal Symptom Rating Scale scores decreasing from 58 to 35, compared to a
modest reduction from 64 to 56 in the placebo group. Quality of life measurements using the Irritable Bowel Syndrome Impact Scale demonstrated similar positive trends, with the FMT group showing more substantial improvements.
Safety considerations
The research team reported only mild and transient side effects, including diarrhoea, bloating, and abdominal pain, with no serious adverse events recorded. “The patients experienced a significant improvement in their quality of life and symptoms, far beyond what we observed with placebo,” notes lead author Katrine Lundby Høyer, MD and PhD student at Aarhus University.
Future directions
While the results are encouraging, researchers emphasise the need for largerscale studies to validate these findings and determine optimal patient selection criteria. “For some patients, this treatment means they can regain control over their daily lives,” says Høyer, highlighting the potential impact on patient care. The study represents a significant step forward in managing diabetic gastroenteropathy, a condition that has traditionally had limited treatment options. Professor Klaus Krogh describes the results as “a breakthrough,” while emphasising the importance of further research to establish implementation strategies.
Reference:
Høyer, K. L., et al. (18 December 2024). Faecal microbiota transplantation for patients with diabetes type 1 and severe gastrointestinal neuropathy (FADIGAS): a randomised, double-blinded, placebo-controlled trial. EClinicalMedicine https://doi.org/10.1016/S2589-5370(24)00579-0
Medical Imaging
Siemens Healthineers expands revolutionary photon-counting CT portfolio with new scanner class
At the recent Radiological Society of North America (RSNA) conference in Chicago, Siemens Healthineers introduced two new photon-counting CT scanners, extending the accessibility of this advanced imaging technology.
Siemens Healthineers has announced a significant expansion of its photon-counting computed tomography (CT) portfolio with the introduction of two new scanners in the new Naeotom Alpha class. The expansion includes the dual-source Naeotom Alpha.Pro and the world’s first single-source photon-counting CT scanner, Naeotom Alpha.Prime, building upon the success of their pioneering Naeotom Alpha system launched in 2021.
The new scanner class represents a fundamental shift in CT technology, utilising cadmium telluride (CdTe) detectors that directly convert X-ray photons into electrical signals. Unlike conventional CT detectors that use a two-stage process converting Xrays to light and then to electrical signals, this direct conversion enables significantly higher spatial resolution and improved contrast-to-noise ratios while also reducing radiation exposure.
“With the launch of the Naeotom Alpha class, we deliver on our promise to make the powerful photon-counting technology accessible to more clinicians and patients,” said Philipp Fischer, head of Computed Tomography at Siemens Healthineers. Technical specifications and capabilities
The portfolio comprises three distinct models. The high-end dual-source Naeotom Alpha.Peak achieves scan speeds of 737 mm/ sec, while the Naeotom Alpha.Pro combines photon-counting precision with dual-source technology for scan speeds up to 491 mm/ sec. The new single-source Alpha.Prime makes the technology accessible to a broader range of healthcare facilities. All systems feature Quantum HD resolution, delivering unprecedented anatomical details at a slice thickness of just 0.2 mm without increasing radiation dose.
In a significant move toward democratizing advanced medical imaging technology, the new NAEOTOM Alpha Prime CT system has been unveiled as an entry-level photon-counting CT scanner. This single-source system represents a strategic approach to making cutting-edge photon-counting technology accessible to a broader range of healthcare facilities, from private practices to major hospitals.
The Alpha Prime maintains the core advantages of photon-counting technology while being optimized for routine clinical operations. It delivers high spectral sensitivity and spatial resolution, though at slightly lower specifications than its dual-source siblings in the Alpha class lineup. Notable benefits include a substantial 35% reduction in radiation dose compared to conventional CT systems, alongside a 25% decrease in contrast agent requirements – both significant advantages for patient safety and comfort.
the system is particularly well-suited for high-throughput environments and routine imaging scenarios. Its capabilities span general oncology, standard scanning procedures, and a comprehensive range of clinical applications, making it an attractive option for facilities looking to upgrade their imaging capabilities without the complexity of dualsource systems.
The system’s market introduction is pending regulatory approvals, with FDA clearance and CE marking expected in early 2024. Initial shipments to customers are anticipated to begin following these regulatory milestones, marking a significant step in the transition toward photon-counting technology becoming the new standard in computed tomography. This development aligns with the broader industry trend of making advanced medical imaging more accessible while maintaining high diagnostic standards.
Clinical applications and workflow optimisation
The technology demonstrates particular promise in cardiac imaging, where the improved temporal and spatial resolution can enhance visualisation of coronary arteries and cardiac structures. The systems incorporate artificial intelligence-driven automation through myExam Companion, which streamlines workflow from patient preparation through image reconstruction and post-processing.
Research and development journey
Development of the photon-counting technology began in 2001, with Siemens Healthineers working alongside research and industry partners to perfect the CdTe detector material. Following extensive prototype testing since 2014, the technology has demonstrated significant clinical benefits, including up to 40 percent reduction in radiation and contrast medium doses.
Clinical validation and impact
More than one million patients have been scanned worldwide using the technology. Prof. Pál Maurovich-Horvat, chair of radiology at Semmelweis University Hospital in Budapest, noted: “With our Naeotom Alpha, we can confidently rule out obstructive coronary artery disease in a greater number of heart patients, particularly those with highly calcified coronaries, eliminating the need for invasive diagnostic procedures in the cath lab.”
Manufacturing investment
To support the expansion of this technology, Siemens Healthineers is investing €80 million in their photon-counting detector production facility in Forchheim, Germany. This investment reflects the company’s commitment to scaling up availability of photon-counting CT technology across different healthcare settings.
Future developments
The systems are currently pending 510(k) clearance and CE mark approval, with expected authorisation in early 2024. As Prof. Gabriel Krestin from Erasmus Medical Center, Rotterdam, stated: “In the future, every CT will be a photon-counting CT,” highlighting the technology’s potential to become the new standard in diagnostic imaging.
Photon-counting CT transforms cardiac diagnostics pathway
Siemens Healthineers’ Naeotom Alpha class of CT enables new capabilities in spectral imaging with ultra-high resolution that is changing how cardiologists diagnose and treat coronary artery disease, reducing the need for invasive cath lab procedures.
Patient pathway transformation
The introduction of Siemens Health ineers’ expanded Naeotom Alpha class of photon-counting CT scanners is en abling a significant shift in cardiac di agnostic capabilities, offering clinicians new tools to evaluate coronary artery disease with greater precision while potentially reducing the need for inva sive coronary angiography. This has the potential to fundamentally change the coronary patient diagnostic pathway.
Clinical benefits in coronary assessment
Recent updates to cardiac imaging guide lines have positioned CT at the forefront of stable chest pain assessment. The Naeotom Alpha’s advanced capabilities, including the new Quantum PURE Lumen technology, enable clinicians to see through calcifications that traditionally obscured vessel evaluation.
“With our Naeotom Alpha, we can confidently rule out obstructive coronary artery disease in a greater number of heart patients, particularly those with highly calcified coronaries, eliminating the need for invasive diagnostic procedures in the cath lab,” explained Prof. Pál Maurovich-Horvat, chair of radiology at Semmelweis University Hospital in Budapest.
Enhanced diagnostic confidence
The system’s Quantum HD Cardiac feature delivers unprecedented spatial resolution, with slice thicknesses as fine as 0.2 mm. This unprecedented capability, combined with spectral imaging, allows for detailed plaque characterisation and more accurate stenosis assessment, particularly in heavily calcified vessels where traditional CT often struggled.
Streamlined workflow integration
The technology incorporates artificial intelligence through myExam Com-
Assessment of cardiovascular diseases: Coronary artery disease kills more people each year than any other disease – and the numbers are rising. Non-invasive cardiovascular diagnostic procedures save time and reduce risks, delivering quick results that help stage disease and guide treatment decisions. In-stent evaluation becomes feasible in clinical routine thanks to the unique combination of resolution, spectral capabilities, and high temporal resolution of Naeotom Alpha.
panion, which automates many aspects of cardiac CT protocols. This includes automated selection of optimal cardiac phases for imaging based on the patient’s heart rate and rhythm, potentially reducing the need for beta-blockers in some cases.
Reduction in invasive procedures
The DISCHARGE trial, involving over 3,500 patients, demonstrated that using CT as an initial diagnostic strategy resulted in fewer major procedure-related complications compared to invasive coronary angiography. The Naeotom Alpha class builds upon these advantages with enhanced imaging capabilities.
Impact on stent evaluation
For patients with coronary stents, the system’s improved spatial resolution and reduced blooming artifacts enable better visualization of in-stent restenosis. Blooming artifacts caused by calcifications appearing
Source: Courtesy of University Hospital Pilsen, Pilsen, Czech Republic
Medical Imaging
on CT images lead to an underestimation of the coronary artery lumen size. Studies have shown higher lumen visibility and lower image noise in stents ranging from 2.5 mm to 4.0 mm in diameter compared to conventional CT systems.
Clinical pathway efficiency
The system’s ability to provide comprehensive diagnostic information in a single scan –including calcium scoring, coronary vessel analysis, and spectral data – can significantly streamline the diagnostic
pathway. This consolidation of imaging needs can reduce the time from initial presentation to treatment decision.
The technology’s potential extends beyond conventional coronary assessment. Ongoing research suggests applications in evaluating pericoronary inflammation through fat attenuation index measurements and quantitative plaque analysis using ultra-high-resolution imaging.
Prof Maurovich-Horvat predicted: “Photon-counting computed tomography will replace conventional CT examina-
How photon-counting CT works: A new
way to see inside the body
Traditional CT scanning has operated like a camera with old-style film – capturing the overall intensity of X-rays passing through the body. Photoncounting CT represents a fundamental shift, working more like a modern digital camera that captures each particle of light individually.
This fundamental change in how we capture medical images represents one of the most significant advances in CT technology since its invention in the 1970s.
The technology employs special crystals made of cadmium telluride that can detect and count individual X-ray photons as they pass through the body. Think of it as the difference between measuring rainfall by looking at how wet the ground is (traditional CT) versus counting individual raindrops as they fall (photon-counting CT).
Each X-ray photon creates a tiny electrical pulse when it hits the detector. The size of this pulse corresponds to the photon’s energy level – similar to how different colours of light have different energy levels. This energy information, previously lost in conventional CT, provides crucial details about the tissues the X-ray passed through.
The detector elements in photoncounting CT are also much smaller than traditional systems. Using the rainfall analogy, it’s like having many small cups
to catch rain rather than a few large buckets. This increased precision leads to sharper im ages with finer detail.
A key advantage is the system’s ability to differentiate between materials based on how they affect X-rays of different ener gies. For example, it can better distinguish between calcium in bones and iodine used as a contrast agent in blood vessels – a task that challenged conventional CT scanners.
The technology eliminates electronic noise – unwanted background signals that can blur images – by only counting X-ray photons above a certain energy threshold. This is similar to how noise-cancelling headphones filter out background noise to deliver clearer sound.
The result is clearer images with up to 40% less radiation exposure and contrast medium use. This makes CT scanning available to more patients, including those who previously couldn’t undergo scans due to radiation concerns or kidney problems that made contrast agents risky.
tions in the medium term.” This transition could fundamentally alter how cardiac patients are evaluated and treated, potentially reducing the reliance on invasive diagnostic procedures while improving diagnostic accuracy.
The integration of these advanced imaging capabilities into clinical practice represents a major step forward in noninvasive cardiac assessment, offering the potential for more precise diagnosis while potentially reducing the need for invasive procedures in many patients.
High precision, scan speed and consistency: Naeotom Alpha.Pro with Quantum Spectral Imaging unlocks the capabilities to evaluate the bone marrow as part of routine scanning while adding morphological details.
The enhanced capabilities of photoncounting CT are opening up new possibilities in medical imaging. The technology is particularly valuable for:
• Cardiac imaging: Allowing clear visualisation of heavily calcified coronary arteries and stents that were previously difficult to assess
• Lung imaging: Providing extremely detailed views of small airways and blood vessels
• Oncology: Enabling better characteri-
sation of tumours and monitoring of treatment response
• Orthopaedics: Offering unprecedented detail of bone microstructure and small fractures
• Paediatric imaging: Reducing radiation exposure while maintaining high image quality
• Emergency care: Allowing wholebody trauma assessment in under three seconds with exceptional detail
Source: Courtesy of University Hospital Pilsen, Pilsen, Czech Republic
New radiotracer technology advances cancer detection and treatment planning
A groundbreaking molecular imaging technique demonstrates exceptional accuracy in identifying and visualising a crucial cancer biomarker, potentially transforming diagnosis and treatment strategies for multiple solid tumours.
Researchers have developed a novel radiotracer that can precisely detect and visualise trophoblast cell surface antigen 2 (Trop2), a significant biomarker present across various cancer types. The innovative imaging agent, [18F]AlF-RESCA-T4, represents a significant development in cancer diagnostics and treatment planning, offering clinicians valuable insights for personalised therapeutic approaches.
The research, published in the December 2024 issue of The Journal of Nuclear Medicine, demonstrates how this new technology can effectively differentiate between cancerous tumours and inflammatory conditions, addressing a critical challenge in cancer diagnosis.
Clinical significance and practical applications
“Trop2 is an emerging biomarker for developing next-generation diagnostic and therapeutic agents for solid tumours and has the potential to be a game-changer for cancer treatment,” says Weijun Wei, MD, PhD, associate research professor at Shanghai Jiao Tong University. “However, efficiently visualizing Trop2 expression and selecting patients who might benefit from Trop2targeted therapies is a clinical challenge.”
The study involved developing two novel Trop2-targeted radiotracers: [18F] AlF-RESCA-T4 and [18F]AlF-RESCART4. Both underwent rigorous preclinical testing in tumour-bearing mice, followed by a pilot clinical trial involving three patients with suspected lung cancer.
Technical innovation and optimisation
The researchers engineered the tracers using single-domain antibodies (sdAbs), the smallest functional antibody fragments de-
rived from camelid heavy-chain-only antibodies. This approach offers several advantages, including high specificity and affinity, rapid targeting within one hour, and reduced immunogenicity.
Particularly noteworthy was the development of [18F]AlF-RESCA-RT4, which demonstrated substantially reduced kidney accumulation compared to its predecessor while maintaining effective tumour detection capabilities. This optimisation addresses a significant concern in radiotracer development regarding organ toxicity.
Clinical validation and future implications
In the pilot clinical trial, [18F]AlF-RESCA-T4 immuno-PET/CT imaging showed promising results in visualising Trop2 expression and differentiating between cancerous and inflammatory conditions. The technology proved particularly valuable in cases where conventional imaging methods presented diagnostic challenges.
Discussing the clinical implications in their paper, the authors emphasise the technology’s potential impact: “Patient selection and response assessment are crucial aspects of molecularly targeted therapies. These processes help identify the most suitable patients for treatment and promptly evaluate their response to therapy.”
The research team also addresses current diagnostic limitations, noting that while “immunohistochemistry is routinely used to determine the expression level of specific biomarkers, it has inherent disadvantages due to sampling biases, nonspecific background staining, and subjectivity in interpretation.”
Advanced diagnostic capabilities
The study revealed significant advantages
of the new imaging technique over conventional methods. As the authors explain: “Immuno-PET involves using radiolabelled antibodies or antibody fragments that specifically bind to the biomarkers of interest. This allows non-invasive imaging and quantification of biomarker expression in various tissues and organs across the body.”
The researchers highlight the technology’s ability to overcome tumour heterogeneity challenges: “Tumours can exhibit spatial heterogeneity, in which different tumour regions may have distinct biomarker expression patterns. This dynamic heterogeneity can impact biomarker expression and treatment response, requiring periodic reassessment before and after the treatments.”
Broader impact on cancer treatment
The technology’s ability to non-invasively visualise heterogeneous and dynamic expression of Trop2 throughout treatment cycles addresses an unmet clinical need. This capability could prove instrumental in selecting appropriate patients for Trop2targeted treatments and monitoring their therapeutic response.
Looking ahead, the research team acknowledges both the potential and ongoing challenges: “With increasing numbers of Trop2-specific antibody therapeutics entering clinical trials, there is an unmet clinical demand to noninvasively visualize the heterogeneous and dynamic expression of Trop2 across the treatment cycle.”
The researchers are continuing to optimise the technology, with plans to translate [18F]AlF-RESCA-RT4 on the uEXPLORER total-body PET/CT scanner for dynamic imaging.
Reference: Huang, W., Cao, M., Wu, Y., et. al. (2024). Immuno-PET/CT Imaging of Trop2 with [18F]AlF-RESCA-T4 Differentiates Lung Cancer from Inflammation. The Journal of Nuclear Medicine, 65(12), 1904-1910. doi: https://doi.org/10.2967/jnumed.124.268751
Novel imaging technique reveals treatment-resistant lung cancers Medical Imaging
Scientists have developed a groundbreaking imaging method that could transform how doctors identify aggressive lung cancers before starting treatment, potentially sparing patients from ineffective chemotherapy whilst opening new therapeutic possibilities.
Treatment resistance remains critical challenge
Non-small cell lung cancer (NSCLC) represents the most common form of lung cancer, with approximately 47,000 new diagnoses annually in the UK. Despite advances in treatment options, including chemotherapy, radiotherapy and immunotherapy, survival rates have remained stubbornly low over the past decade.
A key factor in treatment resistance is the activation of a protein called NRF2, which occurs in roughly one-third of NSCLC patients. The research team notes in their paper, published 17 December 2024 in Nature Communications: “Resistance to therapy is one of the biggest problems in clinical oncology. Despite a revolution in new anti-cancer therapies, such as checkpoint inhibitors and proton beam therapy, durable responses are often not observed due to acquired or innate resistance to existing treatment regimens.”
Novel radiotracer lights up resistant tumours
In an effort to identify treatment-resistant tumours through PET scanning, the researchers, based at King’s College London, repurposed a radioactive imaging agent called [18F]FSPG, currently used in clinical trials. The compound binds to xCT, a protein that appears at high levels in NRF2-activated cancers.
“Currently, there is no quick and early method that shows whether malignant tu-
mours are resistant to treatment,” explains Professor Tim Witney, lead researcher from King’s College London. “Time is essential for patients with lung cancer, and many cannot afford to wait to see if chemotherapy is working.”
Comprehensive validation across multiple models
The research team validated their imaging approach across several experimental models, including laboratory-grown cancer cells, mouse models of lung cancer, and patient-derived tumour samples. The authors report that “[18F]FSPG had area under the curve values approaching 1, at 0.973, 0.996 and 0.990 for orthotopic, GEMM and PDX tumours, respectively,” demonstrating exceptional accuracy in distinguishing resistant from non-resistant tumours.
The imaging technique proved particularly effective in patient-derived xenografts – tumour samples taken directly from NSCLC patients and grown in mice. The researchers found that “there was a high degree of intratumoural heterogeneity of [18F]FSPG retention for both PDX models which was not related to cellularity, as confirmed by ex vivo autoradiography.”
New therapeutic possibilities
Beyond its diagnostic potential, the research revealed that targeting xCT itself could provide a new treatment strategy for resistant tumours. The team tested an antibody-drug conjugate called HM30-
tesirine that specifically targets xCT-expressing cancer cells.
In mice with NRF2-activated tumours, HM30-tesirine demonstrated remarkable efficacy. The researchers report that “HM30-tesirine substantially inhibited tumour growth in H460 tumours compared to vehicle and cisplatin-treated mice over the 6-week treatment study, with effects still present >20 days after the last course of treatment.”
Moving towards clinical implementation
The findings have prompted the initiation of a phase I clinical trial at St Thomas’ Hospital in London, which will recruit 35 patients to evaluate [18F]FSPG imaging in humans. The trial will utilise the hospital’s total-body PET scanner to examine xCT levels before and after treatment.
As the authors conclude in their discussion: “If successful, the combined imaging and xCT-targeted treatment of NSCLC with activating NRF2/KEAP1 mutations may represent a new paradigm for patients with therapy-resistant disease.”
This research represents a significant step forward in personalised cancer treatment, potentially allowing doctors to identify resistant tumours early and select more effective therapeutic strategies for individual patients. The study demonstrates how innovative imaging techniques can not only improve diagnosis but also guide the development of targeted therapies for previously intractable cancers.
Reference: Greenwood, H.E., Barber, A.R., Edwards, R.S., et al. (2024). Imaging NRF2 activation in non-small cell lung cancer with positron emission tomography. Nature Communications, 15(1), 10484. https://doi.org/10.1038/s41467-024-54852-4
Transforming medical education with UpToDate: A talk with Prof. Dr. Mesut Yilmaz
This Expert Insight explores the use of UpToDate in medical education and clinical practice with Dr. Mesut Yilmaz, Head of the Department of Infectious Diseases and Clinical Microbiology at Medipol University, Türkiye.
Physicians in Türkiye navigate a range of emerging challenges and need to stay on top of the latest clinical guidelines, research, and expert insights. After the 2023 earthquake, the country has increased its commitment to supporting public health, including addressing the spread of infectious disease [1]
Prof. Dr. Mesut Yilmaz, Head of the Department of Infectious Diseases and Clinical Microbiology at Medipol University, has witnessed the impact this progress personally, an experience that has only deepened his belief in the value of integrating UpToDate® into medical practice and education across the country. Dr. Yilmaz understands that access to cutting edge research and clinical guidelines has a direct and positive impact on the quality of patient care when it’s needed the most.
Exploring the importance of UpToDate in medical education with Dr. Yilmaz
Q: Can you expound on your role and how you’ve incorporated UpToDate into your practice?
n Dr. Mesut Yilmaz: I’ve used UpTo-
Date since my residency in 2003. Now, as a professor of infectious diseases and clinical microbiology at Istanbul Medipol Univer sity, it’s critical to my role in heading medi cal education. UpToDate is integral to the work of our entire department and serves as a go-to resource for accessing evidencebased information and making informed, productive decisions.
We use it across our curriculum but it starts in our clinical classes, where we em phasize the importance of the tool for all clinicians. By the time students are in their final years, I expect them to openly refer to UpToDate when answering discussion questions. We encourage them to say, “This is what UpToDate advises,” since this en sures they’re working with the most current and reliable information available.
Our graduates are often concerned about losing access to UpToDate after they leave Medipol because it has become such an essential tool.
Q: What are the benefits of using UpToDate in patient care and medical education?
n Dr. Mesut Yilmaz: Using UpToDate directly improves the quality of pa-
apart from other clinical resources?
n Dr. Mesut Yilmaz: UpToDate’s reliability and user-friendly interface are two of the key benefits of using the tool in patient care. This is because leading experts peer review its content. But beyond this, the interface now offers language support, expanding the diversity of clinicians who will find it useful. On the back end, it integrates well with EHRs in many coun-
Dr Mesut Yilmaz
tries, making it indispensable in medical education and practice.
Q: How do you see UpToDate evolving as healthcare continues to change?
n Dr. Mesut Yilmaz: I think UpToDate will include even more features and possibly even expand the personalized recommendations it offers, especially through integrated telemedicine platforms. There’s also definitely potential with AI, which could allow users to interact more dynamically with the tool by asking questions or identifying ways to reduce unnecessary tests and procedures.
Q: Have you seen any stand out stories or memorable experiences using UpToDate?
n Dr. Mesut Yilmaz: We once had a particularly complex case of a severe infection. The treatment plan required a deep understanding of drug interactions and the most recent research. Thanks to UpToDate, our team was able to quickly pull the latest information and immediately adjust the patient’s treatment plan.
This is just one of many examples of how the kind of evidence-based information UpToDate offers can be a game changer in patient care.
Q: What advice would you give to other healthcare professionals about the growing importance of UpToDate in medical education and practice?
n Dr. Mesut Yilmaz: You need UpToDate in your daily practice. With the growing complexity of drug interactions, research, and developments in the medical field, it’s simply impossible to remember every detail that our patients need.
A reliable resource like UpToDate supports your decision-making with the latest evidence in a way that reduces professional errors and even helps mitigate the financial burden of the range of additional resources and subscriptions that
You need UpToDate in your daily practice. With the growing complexity of drug interactions, research, and developments in the medical field, it’s simply impossible to remember every detail that our patients need.
you would need to replicate the benefits that UpToDate offers.
Q: How satisfied are you overall with your experience with UpToDate?
n Dr. Mesut Yilmaz: I can’t overstate the positive experience I’ve had. It’s been a reliable resource across decades of my career and I’m delighted to see how it’s expanded as an indispensable tool – for me in my clinical responsibilities and teaching, and for my students and future doctors that serve the people of Türkiye.
Q: How can the widespread use of UpToDate improve overall health outcomes in Türkiye?
n Dr. Mesut Yilmaz: Our health system struggles under the weight of unnecessary tests and procedures. UpToDate is incredibly useful in addressing this not only by reducing the need for tests, but also streamlining clinical decision making and enhancing efficiency. The end result is improved patient care and enhanced cost efficiency.
Ideally, I would like to see UpToDate considered at a more systemic level, even for the Ministry of Health so that it’s accessible to physicians in our state hospitals. These organizations are in dire need of financial efficiency and UpToDate can reduce the reliance on disparate resources and subscriptions to improve the overall financial health of the system.
The transformative impact of UpToDate on medical education
As more medical education institutions in Türkiye implement UpToDate, more of the country will benefit from evidencebased resources. In the future, with UpToDate’s potential to expand its features, expect to see the tool evolve in ways that further support all levels of health professionals in the country.
• Learn how UpToDate enables clinicians through clinical decision support <https://www.wolterskluwer.com/en/ solutions/uptodate >
About Prof. Dr. Mesut Yilmaz
Prof. Dr. Mesut Yilmaz serves as the Head of the Department of Infectious Diseases and Clinical Microbiology at Medipol University’s Faculty of Medicine. He holds responsibilities as a Vice Dean and is involved in myriad areas of research including pharmacology, toxicology, and general medicine. He is a medical school graduate of Marmara University, Istanbul and from 2007 to 2009, served as an infectious diseases consultant and clinical microbiologist in several private healthcare institutions.
References: 1. https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(23)00362-6/abstract
The original interview is published here: https://www.wolterskluwer.com/en/expert-insights/transforming-medical-education-with-uptodate-with-prof-dr-mesut-yilmaz
Navigating the UAE’s Healthcare Transformation – A Communications Imperative
The UAE’s healthcare sector is undergoing unprecedented transformation, presenting a dynamic landscape of opportunities and challenges. This evolution is driven by ambitious national strategies, rapid technological advancements, and a growing focus on preventative and personalized care. Navigating this complex environment requires a sophisticated understanding of the key trends shaping the future of healthcare in the UAE and a strategic communication approach that resonates with diverse stakeholders.
Kath Harrison, President EMEA at GCI Health, a global integrated healthcare communications agency and part of WPP, offers her expert insights on this evolving landscape and the crucial role of communications in driving success.
A Region Primed for Transformation
The UAE aims to become a global leader in healthcare innovation and delivery. Its commitment to attracting and retaining world-class medical talent has primed the environment for innovation and excellence. Strategies such as ‘We The UAE 2031’ and ‘UAE’s Future Roadmap’ prioritize health as fundamental to economic and societal progress. This aligns with regional efforts to improve population health across the Middle East.
Key Trends Shaping the Future:
Several interconnected trends are shaping the future of healthcare in the UAE:
• Smart Health Systems – The Rise of the Digital-First Approach: The UAE is rapidly adopting interconnected smart health systems that prioritize a digital-first approach. This transformation is propelled by the integration of advanced technologies, including AI-powered diagnostics, robotic surgery, stem-cell research, remote patient monitoring, telemedicine, integrated patient data systems, smart hospitals, and advanced emergency response
systems. These approaches emphasize preventative and personalized care, as demonstrated by initiatives such as the Emirati Genome Project that is building a comprehensive genomic database for tailored medical treatments. The rise of wearable health technology in patient care also empowers individuals to manage their health while offering healthcare professionals valuable real-time insights.
• Addressing Chronic Diseases – A National Priority: Like many regions, the UAE faces the growing challenge of chronic diseases such as obesity, diabetes, and cardiovascular conditions. With diabetes affecting over one million people and obesity incurring an annual economic cost of nearly US$12 billion, these conditions remain a national priority. The National Policy for Promoting Healthy Lifestyles, launched in 2022 as part of the UAE Centennial 2071 plan, underscores the country’s long-term commitment to investing in the health and well-being of future generations. This commitment is further reinforced by a focus on longevity and mental well-being initiatives. There are increased investments in life sciences
research and development, both locally and globally, to drive breakthrough technologies and novel treatments. Strategic public-private partnerships and affiliations with leading medical device manufacturers and renowned research centers worldwide are fostering knowledge exchange and positioning the UAE as a leader in advanced therapies.
• Global Health Security – A Growing Role on the World Stage: The UAE is playing an increasingly prominent role in global health security and strengthening healthcare systems worldwide. This commitment builds upon the humanitarian legacy of the country’s founding father, Sheikh Zayed bin Sultan Al Nahyan, and is reflected in its active participation in international collaborations, knowledge sharing initiatives, and contributions to global health programs. The UAE’s strategic location, advanced infrastructure, and commitment to innovation position it as a key player in addressing global health challenges.
• Value-Based Care – Shifting the Focus to Outcomes: There is a clear shift towards a value-based care model in the
UAE. This approach prioritizes patient outcomes and cost-effectiveness, moving away from traditional fee-for-service models. Value-based care necessitates a greater focus on preventative care, proactive patient engagement, and data-driven decision-making to optimize resource allocation to improve care quality and patient outcomes. This transition requires a collaborative approach involving healthcare providers, payers, and patients to achieve shared goals.
The Evolving Role of Communications in the UAE Healthcare Landscape
This transformative period presents unique communication challenges and opportunities. Organizations operating in the UAE healthcare sector require a deep understanding of local nuances, diverse stakeholder groups, regulatory processes, and the country’s specific healthcare priorities.
• Transparency and Ethics in the Digital Age – Building Trust in a DataDriven World: The increasing use of personalized medicine and AI in healthcare necessitates clear and transparent communication about the benefits, risks, and ethical considerations associated with these technologies. The growing adoption of digital therapeutics (DTx) requires transparency regarding data usage, potential AI biases, and patient privacy. The UAE’s regulated environment positions it to lead the global conversation on ethical guidelines for these technologies, and effective communication is central in building public trust and ensuring responsible implementation.
• Culturally Sensitive Communication – Respecting Diversity and Building Authentic Connections: The UAE’s diverse population, with its rich tapestry of cultures, demands a nuanced and sensitive communication approach. Building a strong brand narrative requires a deep understanding of cultural sensitivities, audience values, and preferred communication channels. Crafting messages that resonate authentically and respectfully with different demographic groups is essential for building trust and achieving communication goals.
• Data-Driven Insights – Shaping Resonant Messaging and Measuring Impact: Data-driven insights are crucial for shaping resonant messaging, tailoring communication strategies, and accurately measuring campaign impact. Analyzing healthcare trends, patient preferences, and media consumption patterns allows for the development of targeted and effective communication campaigns. Data analytics can offer insights into audience engagement and campaign performance, helping organizations optimize and expand their communication strategies.
• Stakeholder Engagement – Fostering Collaboration and Building Strong Relationships: Meaningful engagement with a wide range of stakeholders, including healthcare professionals, patients, policymakers, media representatives, and community leaders, is essential for fostering trust, building strong relationships, driving collaboration and achieving shared goals. Open and transparent communication facilitates effective dialogue, enabling organizations to understand stakeholder perspectives, address concerns, and build consensus around key healthcare issues.
• Digital Innovation – Embracing New Technologies and Reaching Diverse Audiences: Embracing digital innovation is paramount for navigating the dynamic media landscape and achieving communication objectives in the UAE. This includes leveraging influencer partnerships, implementing targeted online campaigns, and utilizing innovative digital platforms and technologies to enhance reach and engagement. Expertise in Web 3.0, digital marketing, and paid media strategies is essential for maximizing the impact of communication efforts and connecting with diverse audiences.
Differentiating Your Healthcare Offering in a Competitive Market
In the UAE’s competitive healthcare market, understanding evolving population needs and aligning with national priorities is key. Organizations that clearly communicate their commitment to population health, preventative care, longevity, and holistic well-
being, while focusing on value-based care, will rise above the competition. Recognizing unique organizational strengths and aligning communications with national goals are vital for boosting brand awareness, credibility, and sustainable growth.
Shaping the Future of Health through Strategic Communication
In this landscape, a strategic, culturally sensitive, and data-driven communication approach is essential. As the region adopts digital transformation and personalized medicine, transparency, proactive engagement, and authentic communication become critical for success. Organizations need to harness data-driven insights, embrace digital innovation, and foster meaningful stakeholder collaboration to support the UAE’s vision of a healthier future and meet their own objectives. By adopting these principles, healthcare organizations can effectively navigate the sector’s complexities and actively contribute to its ongoing transformation.
GCI Health: A fully integrated global healthcare communications agency
At GCI Health, we bring decades of experience across the healthcare spectrum, from life sciences and pharmacology to behavioral health, clinical application, and technology. Our human-first perspective, rooted in the experiences of those we strive to reach, informs our bold yet relevant approaches. With offices spanning the Middle East, AsiaPacific, Europe, and North America, GCI Health offers a global network of dedicated healthcare communicators, delivering exceptional results through local execution.
Connect with Kath Harrison, President EMEA, at Kath.harrison@gcihealth.com or WhatsApp +971 058 516 1589. Follow us at: www.gcihealth.com
Estonia’s Cutting-Edge Healthtech Innovation to Take Centre Stage at Arab Health 2025
Estonia is a pioneer in digital transformation, particularly in its health sector. Since gaining independence in the early 1990s, the nation has evolved into a leader in data-driven healthcare.
As Arab Health 2025 approaches, Estonia’s participation underlines a commitment to revolutionising global healthcare. With a strong portfolio of achievements and a progressive ecosystem, Estonia stands poised to contribute to advancements in the Gulf Cooperation Council (GCC) and beyond, where nations are also embracing emerging technologies.
This article will explore Estonia’s healthtech leadership, the GCC’s digital health initiatives, and opportunities for collaboration to improve patient care and health technologies.
Shared Vision for Digital Healthcare
Today, Estonia is a trailblazer in digital healthcare, with 99% of health data digitised and backed by over two decades of ehealth expertise. Its national digital health system is a blueprint for countries seeking to modernise healthcare through unified, data-driven solutions.
GCC countries share this vision, driving transformation through investments in telemedicine, artificial intelligence (AI), and patient-centric platforms. These efforts seek to create more accessible and efficient healthcare systems, resonating with Estonia’s journey.
Estonia’s Healthtech Innovations
The e-Health Record system – a cornerstone of the Estonian digital healthcare landscape, allows patients easy access to their medical records, ensuring a seamless healthcare experience. Estonia’s top rank in the 2024 Digital Health Index by Bertelsmann Stiftung spotlights its success in integrating technology into healthcare. Placing citizens at the apex of their healthcare systems, has further empowered Estonia to establish new standards for efficiency, accessibility, and patient-centric care – redefining what is achievable in healthcare for nations worldwide.
The Estonian healthtech ecosystem is
rich with cutting-edge solutions that enhance patient care. Arab Health 2025 will demonstrate the significant contributions of several Estonian companies to the field of digital healthcare innovation:
• 7Sense: 7sense is transforming the lives of visually impaired individuals with its Telehaptic Sight™ technology, a noninvasive assistive solution that uses a unique haptic mat to convey objects, motion, speed, and distance through touch. This groundbreaking approach enhances situational awareness, enabling users to navigate open spaces and comprehend their environment effectively. The technology has received incredibly positive feedback from pilot projects launched in Germany, the UK, the Netherlands, and France.
• MDSC Systems: Specialising in medical diagnostics, MDSC Systems enhances crisis response and public health with mobile, deployable solutions for rapid medical aid, diagnostics, and health screenings. The lightweight units enable swift deployment to disaster zones, conflict areas, and remote regions, supporting cancer detection, children’s vision tests, trauma care, and hazardous waste management, ensuring health and safety wherever it’s needed most.
• Helmes: Helmes drives healthtech innovation by creating digital solutions that enhance healthcare efficiency and acces-
sibility. Its flagship e-Prescription platform, launched in 2010, revolutionised Estonia’s healthcare system by seamlessly connecting doctors, patients, and pharmacies through a centralised, paperless system. This transformative solution reduced administrative burdens, minimised errors, and improved patient convenience, achieving nearuniversal adoption within just one year. Helmes offers tailored digital solutions to modernise healthcare systems worldwide, facilitating better patient care and operational efficiency.
• OneArchitects: OneArchitects is at the forefront of designing health-focused environments that elevate patient experiences through innovative architectural solutions. Prioritising patient comfort and functionality, the firm creates spaces that not only meet the needs of healthcare providers but also promote healing and wellbeing. Their commitment to thoughtful design results in environments that foster recovery and enhance overall health outcomes. With a keen understanding of the interplay between architecture and patient care, OneArchitects transforms healthcare facilities into welcoming, efficient spaces that inspire trust and reassurance.
• Nortal: Nortal specialises in creating seamless, data-driven solutions that bridge public and private sectors. They have pro-
pelled Estonian healthcare by developing the National Health Record, enabling secure, real-time data exchange among providers and patients. This success, along with blockchain integration for record security and international e-health projects, highlights Nortal’s expertise in building efficient, patient-centric healthcare solutions worldwide.
• Chemi-Pharm: As a leading hygiene specialist, Chemi-Pharm is dedicated to enhancing safety and cleanliness in the medical sector. The company has over 20 years of experience in developing and distributing disinfectants, cleaning, and skincare products tailored for professional use, offering a comprehensive product line that meets high industry standards. Supported by in-house research and development in collaboration with top European researchers, Chemi-Pharm’s innovative solutions prioritise efficacy and minimal allergenic properties, ensuring optimal hygiene and patient safety.
• Lifeyear: Lifeyear is redefining cardiovascular care through innovative digital health solutions aimed at extending the human healthspan. Its AI-enabled Softwareas-a-Medical-Device platform integrates clinical guidelines, remote patient monitoring, and behavioural science to provide personalised interventions. By leveraging real-time data, Lifeyear improves the management of risk factors such as hypertension and obesity, enhancing patient outcomes. With a dedication to transforming healthcare delivery, Lifeyear strives to promote a healthier future for individuals globally.
• Migrevention: Migrevention supports healthcare professionals through its digital headache clinic, which streamlines patient access to care for migraines and tensiontype headaches. The platform enhances communication, reduces administrative burdens, and facilitates efficient management of headache conditions. With a focus on patient needs, Migrevention enables healthcare providers to deliver targeted interventions and personalised care. Committed to evidence-based practices, Migrevention develops tailored digital solutions that improve the understanding and manage-
ment of primary headache disorders, leading to better patient outcomes.
• Nordic Vitamins: Nordic Vitamins specialises in developing advanced dietary supplements that utilise innovative delivery systems for enhanced absorption. With decades of pharmaceutical experience, the company offers high-quality products tailored to meet diverse client needs across Europe and beyond. By prioritising the highest industry standards, NorVita aspires to improve health and wellness through science-backed solutions.
These companies are creating a collaborative ecosystem that drives innovation, nurturing the development of integrated healthcare solutions.
GCC’s Digital Healthcare Transformation In line with the UAE’s Vision 2031 and Saudi Arabia’s Vision 2030 to prioritise healthcare through digital innovation, UAE and Saudi Arabia are making substantial investments in digital health initiatives.
Estonia’s e-health technologies offer valuable insights for GCC countries aiming to modernise healthcare systems. With an emphasis on data-driven solutions and seamless interoperability, Estonia demonstrates how unified systems can improve efficiency and patient care.
“Global healthcare is evolving with trends like data-driven care, preventive solutions, and telemedicine. Estonia’s leadership in e-health systems and personalised medicine aligns with the Gulf’s vision for smarter, resilient healthcare. Companies like Helmes and Nortal have shaped Estonia’s digital health infrastructure, while Migrevention and Lifeyear tackles challenges like headaches and heart conditions, underscoring how Estonian innovation drives meaningful advances in global healthcare accessibility and patient outcomes,” said Reet Reinart-Okugbeni.
Reet Reinart-Okugbeni, PhD, is the R&D Expert at Estonia’s Applied Research Program, fostering collaboration within Estonia’s Healthtech sector to drive innovation and global partnerships.
Opportunities for Collaboration
Partnerships between Estonian healthtech companies and GCC healthcare providers are crucial to exchange expertise in datadriven health systems, genomic data, and digital platforms, ensuring more efficient healthcare. Collaborations in personalised medicine can harness the strengths of both ecosystems for global advancements.
Estonia’s digitalisation journey has prioritised privacy and data security through robust regulatory frameworks and encryption technologies, ensuring compliance with data protection laws and building public trust. Its success in creating a technology-driven healthcare model serves as a roadmap for other nations to elevate their healthcare systems. GCC countries can accelerate their digital initiatives by drawing on Estonia’s expertise.
Trending in the Estonian Healthtech sector
Estonia has emerged as a global leader in health technology, driven by its advanced e-health systems, genomic research, and AI-driven solutions. Through Enterprise Estonia’s Applied Research Program, the nation has invested over €100 million since 2021, supporting 170+ innovative projects. This programme facilitates high-value entrepreneurship, enabling Estonian companies to develop and launch advanced healthcare technologies globally.
Looking ahead, Estonia will leverage emerging technologies like machine learning, predictive analytics, and AI to develop responsive and personalised healthcare.
The Bright Future of Healthcare
Estonia exemplifies what can be achieved when a nation embraces innovation, providing seamless, accessible, and personalised care that empowers its citizens and showcases the potential of a fully integrated healthcare system.
Estonia’s digital health acumen aligns with GCC’s ambitions, setting the stage for impactful partnerships. As both regions continue to explore innovation, they can create a global model for technology-driven, personalised healthcare solutions that improve access while cultivating a patientcentric approach.
• Visit Trade Estonia at: https://tradewithestonia.com/events/arab-health-2025/
Partnership powers precision healthcare provision in emerging markets
Technical advances in diagnostic imaging have historically faced barriers to widespread implementation in low and middle-income countries. In an effort to overcome these barriers, Siemens Healthineers’ Value Partnerships programme is working to bridge this divide through innovative deployment strategies and long-term collaborations, aiming to improve healthcare accessibility across developing regions.
Strategic solutions for sustainable healthcare
In an exclusive interview with Middle East Health, Dr Bernd Ohnesorge, Head of Europe, Middle East and Africa at Siemens Healthineers, outlined the company’s ambitious vision to reach 3.3 billion patients globally by 2030, with 1.25 billion of those in low and middle-income countries. The Value Partnerships initiative represents a significant paradigm shift from traditional equipment sales to comprehensive, decade-long collaborations with both government and private healthcare providers.
“Where you live should not determine if you live,” Dr Ohnesorge emphasised, highlighting how the programme addresses healthcare access disparities in both developing regions and remote areas of high-income nations. These partnerships encompass not only technology provision but crucially include ongoing maintenance, staff training, and digital knowledge transfer solutions – essential components often overlooked in traditional healthcare technology deployment.
Technology adaptation meets local needs
Recent technological innovations are proving particularly suitable for emerging market deployment. Dr Ohnesorge cited their latest MRI platforms, which require minimal infrastructure investment and reduced energy consumption through innovative helium management. However, he noted that core diagnostic technologies themselves often require less market-specific adaptation than might be expected, challenging conventional assumptions about technology deployment in developing regions.
“High-throughput core technologies in CT, MRI, and X-ray aren’t inherently different whether deployed in Africa, Japan, or Germany,” Dr Ohnesorge explained. “The key differentiation lies in the surrounding ecosystem – particularly in training, digital-
isation, and AI-assisted operations that can help address staff shortages and expertise gaps.” This insight has led to the develop ment of sophisticated digital solutions that enable remote knowledge sharing and vir tual consultation capabilities.
The programme has already demonstrated significant success through several major deployments. In Rwanda, Siemens Health ineers has established a groundbreaking 10year partnership with the government to pro vide comprehensive imaging services across large portions of the country. Private sector collaborations are also proving effective, with substantial partnerships established with the NetCare group in South Africa and the Dallah group in Saudi Arabia, each demonstrating different models of successful implementation.
Addressing implementation challenges
A critical aspect of the Value Partnerships approach is its focus on lifecycle management. Dr Ohnesorge highlighted how traditional funding mechanisms often focus solely on initial equipment acquisition, leading to eventual equipment abandonment due to lack of maintenance or trained operators – a persistent challenge in healthcare technology deployment across developing regions.
“We frequently encounter unused equipment across Africa that was purchased and installed but now sits idle,” Dr Ohnesorge noted. “Our partnerships specifically address this through long-term service agreements and continuous education programmes that account for staff turnover.” This comprehensive approach ensures sustained operational capability and maximises the long-term value of healthcare investments.
Digital innovation driving accessibility
The integration of artificial intelligence and digital solutions plays a crucial role in the programme’s success. Advanced AI tools assist in patient positioning, scan optimisa-
tion, and clinical decision support, helping to bridge expertise gaps and enhance operational efficiency. These digital innovations are particularly valuable in regions facing healthcare professional shortages, enabling more efficient use of available resources.
A training centre has already been established in Egypt in collaboration with government authorities, focusing on technical and engineering education for both public and private sector professionals. This hub serves as a model for future educational initiatives across the region.
Looking ahead, Siemens Healthineers continues to develop technologies that balance advanced capabilities with practical deployment considerations. Their latest MRI platform, featuring an enlarged bore for improved patient comfort and reduced installation requirements, has already seen rapid adoption in North Africa, with ten units deployed within months of launch –demonstrating the region’s appetite for advanced medical technology when delivered through appropriate partnership models.
As healthcare systems globally struggle with staff shortages and access disparities, this comprehensive partnership approach offers a template for future healthcare technology implementation in emerging markets.
Dr Bernd Ohnesorge, Head of Europe, Middle East and Africa at Siemens Healthineers.
Discover the latest MEIKO innovation at Arab Health
What makes the latest MEIKO innovation so special? How can the new TopLine M2 optimise the cleaning and disinfection process? This is best explained by people who work with it every day: the employees of the BDH clinic in Elzach, Germany.
We are carers – not machine operators! “Insert care utensils – and you’re done! – It runs itself.” That is Claudia Ganz discussing the cleaning and disinfection process for care utensils in the new TopLine M2 appliances. Previously, many more touches were needed: open the machine door, insert the bedpan into the machine, along with the contents, shut the machine door. Find, select and start the right programme. Then rush off to wherever you are needed!
These days it is just one simple movement and a quick look to check – and that is all the human input needed in the sluice room. The rest is down to the TopLine M2.
Contact-free operation
This is all down to a feature that is new to the market: load detection by MEIKO. The assistant system suggests the correct cleaning programme for the care utensils loaded and starts it automatically after a few seconds. When combined with automatic door opening and closing – available with either a hand sensor or foot switch depending on version – you don’t even
need to open or close the door by hand.
“Making things as easy as possible helps us to keep more time available for our actual jobs. I think that is an important role that technology can play in our sector,” says Claudia Ganz. And that was one of the ideas behind the development of this product. “So that carers can go about caring! So they are not caught up with operating these machines all the time.”
Smooth running
Has the programme already ended? Is everything running smoothly? The new TopLine M2 appliances communicate this information using status displays, progress bars and coloured lights. Blue means ‘ready for operation’, green is for ‘washing’ and red shows that there is an ‘important message’.
“That means that just walking past in the corridor, I can see whether the machine is still flashing green and I have time to see another patient or whether I can go and start unpacking,” explains Nadine Heizmann, one of the nurses as BDH Clinic Elzach.
Hygienically safe cleaning and disinfection
Claudia Ganz is also a hygienist through and through – so the cleaning performance had to win out, too. And it did –with flying colours.
BDH Clinic Elzach specialises in neurological rehabilitation, both general and early. That means: lots of patients in need of care; and lots more wash bowls, urine bottles, bedpans and kidney dishes that have to be cleaned and disinfected after
use. “We have machines that can easily manage 15,000 loads per year. More, even.” An optimally designed wash chamber with the wash arm on the roof and nozzles to provide high washing pressure from the perfect positions come together to ensure a hygienic clean both inside and out for items entrusted to the TopLine M2. Plus an adjustable A0 value of up to 12,000 ensures that BDH Clinic Elzach is equipped for the future.
Experience the Topline M2
Arab Health is coming up – and with it the opportunity to experience the first washer-disinfector with an assistant system by MEIKO: TopLine M2, the new pearl in their care collection, live at booth H10 in the Saeed Arena.
• You can register here: www.meiko.com/en/arab-health
• For more information, visit: www.meiko.com/en/arab-health
Claudia Ganz
Siemens Healthineers
Siemens Healthineers introduces a patient-centric and experience-driven concept at Arab Health 2025
From January 27 to January 30, 2025, Arab Health, the leading healthcare exhibition in the Middle East, opens its doors again. Celebrating its 50th anniversary, once again the conference will showcase all the latest trends of the industry under this year’s slogan “Where the world of healthcare meets”.
Upholding their purpose – “We pioneer breakthroughs in healthcare. For everyone. Everywhere. Sustainably.” – Siemens Healthineers, one of the world’s leading medical equipment manufacturers, will create a story for visitors on booth S1.C10 in Sheikh Saeed Hall 1, centering around three core themes:
• Overcoming the world’s most threatening diseases such as cancer and stroke and how this can lead to high-quality individualized care.
• Access to care, explaining their endeavours to make quality and affordable healthcare accessible and available to everyone, everywhere.
• Sustainability, showing how to create new possibilities in a world of limited resources.
This year, Siemens Healthineers is introducing a reimagined presentation concept, designed to mirror the clinical pathway navigated by healthcare providers and patients alike. Visitors will delve into patient journeys across oncology (breast, liver & lung cancer), neurology (stroke management) and cardiology, seamlessly connecting these experiences to Siemens Healthineers’ innovative solutions in diagnostic imaging, laboratory diagnostics, and cancer therapy.
Vivek Kanade, Managing Director Siemens Healthineers, Middle East and Africa, highlights: “For Arab Health’s anniversary, we very much look forward to engaging with our customers and visitors with our new concept, taking them on a patient-centric and more tangible journey along the clinical pathways. We will showcase how we – as an open team of global experts – apply deep clinical knowledge, digital innovation, and data driven insights to improve the health and well-being of
all people and to overcome the most threatening diseases. Together.”
Computed Tomography
Siemens Healthineers recently shook up and transformed the medical imaging industry, introducing the first photoncounting computed tomography scanner. On day 1 of Arab Health 2025, the audience will experience the product launch of one of the new Alpha class scanners, the NAEOTOM Alpha.Prime with proven Quantum Technology, enabling profound clinical impact, supported by AI-powered productivity solutions and addressing the challenges of conventional CT scanners.
Magnetic Resonance Imaging
Another brand-new product will be launched amongst their Magnetic Resonance Imaging solutions. The medical technology company will introduce the region to their next-generation 1.5T MRI platform, entering in a new sustainable era of AI-powered and helium-independent MRIs. The MAGNETOM Flow. Platform will empower users with simplified workflows, elevated patient experience and pioneering AI-enhanced imaging, envisaged to bring the highest-quality results at high speed, coming with a 70cm bore and flexible XL coil for improved patient comfort.
Ultrasound
From the Ultrasound scanning portfolio, visitors will receive hands-on scanning experiences with the latest models of ACUSON Juniper, ACUSON Maple, ACUSON Origin and the new and industry-first ACUSON Sequoia 3.5 with advanced AI for abdominal scanning, improving both examination and reading workflow through view identification and protocol standardization, while automatically labelling and measuring organs in milliseconds.
Molecular Imaging
In the Molecular Imaging section, the med-
tech company will provide insights on their Symbia Pro.Specta SPECT/CT as well as on their latest launch of 2024, the Biograph Trinion. A future-forward PET/CT scanner by design, delivering all you need to make confident diagnostic decisions with outstanding small lesion detectability, excellent quantification, ultra-fast time of flight performance, and lower doses.
X-Ray Imaging
Visitors will also be able to get a hands-on look and feel of the latest additions to our X-Ray Imaging portfolio. The LUMINOS Q.namix is ushering a new era in Fluoroscopy, a truly multifunctional imaging platform for fluoroscopy, radiography, and beyond, providing maximum utilization and peak performance. The MAMMOMAT B.brilliant is a mammography system introducing a new dimension in image quality with an unprecedented level of patient-centricity.
Beyond focus topics and their latest innovations, Siemens Healthineers will guide visitors on a digital journey of recent and ongoing partnerships in the region, emphasizing their commitment to supporting public and private partners in future-proving their local healthcare systems. This journey will be complemented by well-received and engaging insights on Digital & Automation topics as well as the latest news in Laboratory Diagnostics, Value Partnerships and Asset Lifecycle Management.
The anniversary edition of Arab Health promises to deliver profound insights and high-quality discussions about current and future burning topics of the industry and will as usually contribute its share to paving the future of healthcare in the Middle East and beyond.
Visit Siemens Healthineers at Arab Health Booth S1.C10 in Sheikh Saeed Hall 1.
HUMAN Diagnostics
HUMAN’s vision: empowering everyone around the world to access life-saving diagnostics for a healthier future
• Comprehensive portfolio with more than 400 in-vitro diagnostic products in 13 segments
• Broad network of long-standing distribution partners in 160+ countries
Since its foundation in 1972, HUMAN has been developing and marketing comprehensive solutions for the in vitro diagnostics (IVD) market. The comprehensive portfolio ranges from classical clinical chemistry to innovative molecular diagnostic methods as well as special applications such as assays for autoimmunity testing.
Headquartered in Wiesbaden, Germany, HUMAN maintains regional sales offices in the United Arab Emirates, Singapore, China, India, Panama, and has local HUMAN representatives in many other countries enabling a truly global reach.
With almost 300 employees from over 40 nations, its worldwide service and delivery capabilities, and a broad network of long-standing sales partners, HUMAN supports medical laboratories in more than 160 countries.
German quality standards with a global impact
At the production site in Magdeburg, scientists work with modern technologies to drive further developments and innovations, focusing on clinical chemistry, hematology, hemostasis, and immunoassays “Made in Germany”, and in compliance with the highest European quality standards.
“German values, coupled with a global perspective, have always been – and always will be – the cornerstone of our mission to provide diagnostics worldwide,” says Diederik J. van Vliet, Managing Director of HUMAN since 2025. “For more than 50 years now, we have been helping to improve global healthcare outcomes. With our comprehensive portfolio, we cover a wide range of regional needs, from semi-automated devices to fully automated solutions. Through our logistics and services, we are a recognized partner to numerous governmental and non-governmental organizations (NGOs), supporting medical care, particularly in crisis areas.”
HUMAN’s next-generation clinical chemistry instruments have undergone a major functional and design update and will be relaunched at Medlab Middle East 2025 in Dubai.
Focus product lines
Clinical chemistry:
HUMAN offers a broad range of routine and specialty tests in a variety of package concepts to serve the needs of modern state-of-the-art laboratories. In the same way, all HUMAN analyzers and systems emphasize functionality and modern workflow requirements to meet customer and market demand.
Hematology:
HUMAN’s automated hematology products are designed for small to large laboratories and range from 30 to 80 samples throughput per hour. HUMAN offers both 3-part and 5-part differential systems with specially developed and dedicated reagents suitable for human and veterinary applications.
Hemostasis:
HUMAN offers laboratories integrated hemostasis test solutions with HEMOSTAT reagents and HumaClot analyzers. Semi-automated, as well as fully automated HumaClot analyzers support an accurate and economical assessment of the coagulation status. The applications of the HEMOSTAT reagents are pre-programmed and fully validated. The HUMAN coagulation portfolio includes a broad range of commonly performed screening parameters, indicating medical disorders related to coagulation and fibrinolysis.
CLIA | FIA Immunoassay systems:
Chemiluminescence- and fluorescence-based immunoassay systems are platforms that complement each other perfectly. HumaCLIA 150 is the ideal immunoassay system for testing in central and more remote laboratories. HumaFIA on the other hand fits into small to medium throughput laboratories and is intended to run low throughput parameters also as a backup system for HumaCLIA 150.
Discover the comprehensive product portfolio at https://tinyurl.com/vt8h2xw7
Scroll through the eventful history of HUMAN, its milestones and product highlights at https://tinyurl.com/4cr34nek
For inquiries contact our regional sales representatives: HUMAN Diagnostics Middle East FZE Office: Q3 – 198
P. O. Box 122348 Sharjah
U. A. E.
Phone: +971 6 5578650
E-mail: middleeast@human.de
Groundbreaking new X-ray QA testing tool: Meet Mako!
RTI Group has launched Mako, a revolutionary X-ray meter setting a new standard in X-ray Quality Assurance (QA) and testing. Mako delivers unmatched accuracy (±1.5% kVp uncertainty), efficiency, and versatility across all X-ray applications, with a modular design for ultimate flexibility.
Mako’s next-generation detector technology enables precise measurements, while its fully wireless system ensures simple setup and future-proof configuration. Covering Radiography, Fluoroscopy, Mammography, Dental, and CT applications, Mako offers the widest application range in X-ray QA testing, integrating multiple probes simultaneously for seamless performance.
A complete solution
Mako isn’t just a tool – it’s a complete solution to protect patients and staff, ensure optimal image quality, and prolong system lifespan. It integrates seamlessly with RTI’s software and cloud solutions for unparalleled efficiency, full traceability, and streamlined data collection.
Key innovations include the Mako R/F Probe with superior dynamic range and noninvasive mAs capability, and the Mako Mammo Probe, which covers the entire mammography kV range (18–49kV) with exceptional accuracy. For dental X-rays, Mako’s narrow yet highly sensitive sensor outperforms competitors, even in narrow-beam settings.
Mako supports a broad range of QA
measurements, including DAP, mAs, CTDI, and light output, making it the ultimate solution for any X-ray QA need. Complemented by RTI’s industry-leading 10-year warranty, extensive calibration cycles, free online training, and dedicated support, Mako embodies RTI’s mission of “Setting the standard for the Quality Assurance of X-ray imaging.”
Dr. Michael Olding, RTI’s Head of Product Management, states: “Mako combines unparalleled accuracy with a no-fuss setup, delivering the best-ever sensitivity and efficiency for users.”
Discover more about Mako and book your free demo today at makobyrti.com or contact: sales@rtigroup.com.
New test brings precision forecasting to early-stage lung cancer outcomes
Researchers at the Francis Crick Institute, the UCL Cancer Institute and UCLH have shown that a test called ORACLE can predict lung cancer survival at the point of diagnosis better than currently used clinical risk factors. This could help doctors make more informed treatment decisions for people with stage 1 lung cancer, potentially reducing the risk of the cancer returning or spreading.
A study published recently in Nature Cancer, involving 158 lung cancer patients from the TRACERx cohort, showed that the ORACLE test could identify stage 1 patients at higher risk of disease recurrence who might benefit from additional interventions beyond surgery. This addresses a significant clinical challenge, as approximately 25% of stage 1 patients experience cancer recurrence under current treatment protocols.
Overcoming sampling limitations
ORACLE’s methodology tackles a fundamental challenge in tumour assessment by examining gene expression patterns across entire tumours, circum-
venting the traditional limitation of analysing only small tissue samples that may not represent the tumour’s full genetic diversity.
The researchers evaluated ORACLE against 359 lung cancer therapeutics, finding that high ORACLE risk scores correlated with better responses to platinum-based chemotherapy agents. This association stems from increased chromosomal instability in tumour regions with elevated ORACLE scores, making them particularly susceptible to platinum drugs.
Future directions
“ORACLE can now predict survival rates in patients diagnosed at the earliest stage,” says Dhruva Biswas, Translation Fellow at the Crick Institute and co-first author. “If
validated in larger cohorts of patients with lung cancer, doctors could one day use ORACLE to help make informed treatment decisions, bringing lessons from cancer evolution into the clinic.”
The research team is currently working with industry partners to advance ORACLE towards clinical implementation, with the aim of offering a more sophisticated approach to treatment stratification in early-stage lung cancer patients.
Reference:
Biswas, D., Liu, Y. H. et. al. (9 January 2025). Prospective validation of ORACLE, a clonal expression biomarker associated with survival of patients with lung adenocarcinoma. Nature Cancer https://doi.org/10.1038/s43018-024-00883-1
Novel surgical mesh design advances uro-gynaecological treatment options
Swiss medical device innovation offers enhanced biomechanical properties for improved patient outcomes in urinary incontinence and pelvic reconstruction procedures.
Innovation in surgical mesh design
A pioneering surgical mesh technology developed through collaboration between APIS Technologies and the French Institute for Textile demonstrates superior mechanical properties specifically engineered for urogynaecological applications. The I-STOP range of implants represents a departure from traditional surgical meshes, which have historically been adapted from hernia repair materials.
Technical advancement in biomaterial engineering
The technology centres on a unique weaving structure for polypropylene monofilament, developed in the early 2000s. Unlike conventional surgical meshes, the I-STOP design exhibits remarkable shape retention characteristics, demonstrating seven times greater recovery following mechanical loading compared to traditional options. This property ensures consistent urethral support, a crucial factor in maintaining long-term therapeutic efficacy.
Material properties and clinical implications
Critical to the innovation is the mesh’s resistance to deformation, showing five times less structural alteration under stress compared to widely used alternatives. This stability maintains consistent pore geometry, a feature recognised as essential in preventing post-surgical complications such as infection and erosion. Additionally, the implant achieves a significant reduction in material mass, weighing half that of conventional meshes, adhering to the principle that minimal implanted material optimises biocompatibility.
Clinical validation and research outcomes
Multiple peer-reviewed studies have validated the technology’s efficacy. Research published in European Urology <https:// doi.org/10.1016/j.eururo.2005.09.019> highlights the significance of nonelastic properties in immediate postoperative outcomes. A subsequent study in the Journal of Minimally Invasive Gynecology <https://doi.org/10.1016/j. jmig.2010.08.105> confirms the maintenance of these mechanical properties following implantation, with no observed emergence of voiding dysfunction during follow-up periods.
Recent long-term findings
More recent research, published in the Journal of Clinical Gynecology and Obstetrics in 2020 <https://doi.org/10.14740/jcgo643> demonstrated notably low rates of meshrelated complications. The study specifically observed reduced instances of erosion, exposure, and contraction, attributing these favourable outcomes to the unique structural properties of the I-STOP design.
Applications and availability
The technology has been implemented across three distinct products: a female urinary incontinence sling based on the Ulmsten technique, a male urinary incontinence sling, and a range of meshes for female pelvic reconstruction. All variants maintain the core technological advantages while offering specific dimensional and structural modifications for their intended applications.
The innovation represents a significant advancement in uro-gynaecological surgery, offering improved biomechanical properties while addressing historical concerns regarding mesh-related complications. This Swiss-developed technology demonstrates how specific engineering of surgical materials for their intended application can lead to improved patient outcomes in reconstructive surgery.
The products are currently available through APIS Technologies, headquartered in Switzerland.
• Visit APIS Technologies: www.apis.swiss
Messe Düsseldorf reaches first milestones in reshaping its Asian business
MEDICARE ASIA unites nine healthcare trade shows under one roof
Since April 2024, Singapore serves as the headquarters of the “Messe Düsseldorf for Asia” network (MDfA), which is gradually integrating Messe Düsseldorf’s Asian business. In the same year in September, Marius Berlemann, new Chief Operating Officer, announced the unification of the company’s nine Asian healthcare trade fairs under the umbrella of MEDICARE ASIA headquartered in Singapore.
With MEDICARE ASIA, Messe Düsseldorf is creating an Asia-wide platform for the continent’s growing medical technology and rehabilitation market, comprising nine trade shows in China, India, Singapore and Thailand. The portfolio includes MEDICAL FAIR ASIA (Singapore), MEDICAL MANUFACTURING ASIA (Singapore), MEDICAL FAIR THAILAND (Bangkok), MEDICAL FAIR CHINA (Suzhou), REHACARE CHINA (Suzhou), MEDICAL FAIR INDIA (Mumbai, New Delhi) and FAMDENT Show (Mumbai, Hyderabad).
Driving the Change
Marius Berlemann, Chief Operating Officer of Messe Düsseldorf Group, emphasizes the necessity of a strong position in Asia: “MEDICARE ASIA reinforces our global and strategic leadership in healthcare trade fairs. Building on the success of internationally renowned exhibitions like MEDICA, COMPAMED, and REHACARE in Düsseldorf, Germany, we are now leveraging our expertise in Asia
to establish a strong trade show network by 29%.
Focus
on Healthcare
In particular, the healthcare market holds significant potential: Asia represents nearly half of the world’s population, with increasing wealth and demands for healthcare services. In India, healthcare expenditures are expected to rise by 182.3% between 2022 and 2030, in Indonesia by 71%, in China by 52.4%, and in Japan by 35%. For this reason, “Messe Düsseldorf for Asia” has focused on healthcare exhibitions from the beginning. A team of highly specialized ex-
MEDICA, COMPAMED, and REHACARE exhibitions in Düsseldorf. Shirley Lim explains the benefits of this network: “The demand for healthcare is increasing across Asia, and at the same time, the topics of care and inclusion are gaining relevance. We provide the marketplaces to meet this demand and advance these important issues. With MEDICARE ASIA, we will continuously enhance and expand this portfolio. Customers will benefit from harmonized offerings in Asia that are tailored to regional needs, central points of contact and even stronger business platforms – both in Asia and Düsseldorf.”
New Technogym Checkup measures your physical
Starting from the analysis of your physical and functional conditions, the innovative AI-based assessment station calculates your Wellness Age and automatically prescribes your ideal training protocol, that adapts over time.
Numerous scientific studies demonstrate that regular physical exercise and healthy lifestyles are key elements in achieving healthy longevity, meaning living longer in good health. Regular physical exercise is a powerful medicine, but it requires precise posology, and Technogym can prescribe the ideal training protocol for you thanks to the analysis of your physical parameters and artificial intelligence.
New Technogym Checkup – the innovative AI-based assessment station –targets your training depending on your physical and functional parameters and, by leveraging artificial intelligence, it obtains the prescription of a precision program tailored to your needs, goals, and conditions
After logging in with Technogym App, Technogym Checkup will measure your body composition, strength, balance, mobility, and cognitive abilities through precise and reliable tests. The data collected with Technogym Checkup, available within Technogym Ecosystem, will be processed by Technogym AI Coach – Technogym’s AI digital trainer – and
transformed into a personalized training protocol, based on real data and always at your fingertips, ensuring a precision training experience and improving your lifestyle from all angles. Thanks to Technogym Ecosystem, you can access your training program anywhere and anytime: at the gym, at home, in a hotel, at work, or with your doctor.
Additionally, Technogym Checkup calculates your Wellness Age, the age mirroring your physical and functional conditions. With this starting point, you can progressively improve thanks to your targeted precision training program while decreasing your Wellness Age, to make you healthier. Thanks to AI, the training program adapts over time to be closer to your goals: superior results faster.
For industry operators, Technogym Checkup represents a great opportunity to offer their members an innovative, unique, personalized service capable of ensuring a frictionless training experience: from the first access and program configuration, to training on Technogym equipment. From a business perspective, Technogym Check-
up represents an excellent opportunity to attract new customers, retain existing ones, and offer services capable of generating additional revenue.
Technogym
Founded in 1983, Technogym is a worldleading brand in fitness, wellness, sport, and health. Technogym provides a complete Ecosystem made of connected smart fitness equipment, digital services, and training content. Thanks to the Mywellness Cloud Platform people can connect to their personal training experience anywhere, both on Technogym equipment and mobile devices. With over 2,500 employees Technogym is present in over 100 countries. More than 85,000 Wellness centers and 400,000 private homes in the world are equipped with Technogym. Technogym has been appointed Official Supplier to the Paris 2024 Olympics for the ninth time, after Sydney 2000, Athens 2004, Turin 2006, Beijing 2008, London 2012, Rio 2016, Pyeongchang 2018 and Tokyo 2020, and it’s the reference brand for the training of worldwide champions.
The answer for the need for pharmacy automation: CONSIS H solution for hospital outpatient pharmacies Willach Pharmacy Solutions
With a population of more than 490 million people, the MENA region is one of the world’s largest healthcare markets.
The MENA Pharmacy Automation Market is projected to grow at a CAGR of 6.7% during the forecast period to reach a total market size of US$226.21 million by 2028 from US$143.38 million in 2021.
Increasing healthcare expenditure is driving the demand for pharmacy automation in the region to provide improved service to a large patient base. Pharmacy staff require modern technology tools to perform their jobs efficiently without losing on patient safety or care quality.
Hospital outpatient pharmacies, busy with dispensing prescriptions, find it challenging to focus on additional revenue streams and so pharmacy automation is attractive to improve the speed, space and accuracy of dispensing.
Medication dispensing and patient consultation take time and where efficiency is critical to maximize the potential of this revenue generating department, rush mode can mean finding yourself with costly, even dangerous, errors on your hands.
Pharmacy automation allows the pharmacy staff to improve customer service, reduce dispensing errors and workloads, as well as add a higher level of security, tracking and accountability.
The key benefits are:
• Speeding up the dispensing process
• Cutting down on dispensing errors
• Saving space on product storage
• Creating more room for consultation.
Willach Pharmacy Solutions can offer a 100 % customized design which is adapted to your available space, workflow, budget, and business growth without changing the available space and knocking down any walls.
CONSIS H robot
All key benefits are covered by the CONSIS H robot – the fast, simple and reliable principle capable of providing this over a long period of time with its parallel dispensing from several storage channels.
Some of the Willach Pharmacy Solutions reference projects in MENA include solutions with automatic dispensing CONSIS robots and FAMA storage and dispensing systems provided in Saudi Arabia at John Hopkins ARAMCO Hospitals (Al Khobar and Al Hasa) and at Al Dawaa Pharmacies King Saud Medical City (Riyadh); in Kuwait at the MoH Hospital Jaber
Al Ahmad; and in Oman at the Medical City for Military and Security Services.
The CONSIS robots and FAMA storage and dispensing systems reliably cover a dispensing volume of at least 10,000 packages per day for many years.
Willach Pharmacy Solutions provides all solutions for dispensing and storage areas in hospitals and community pharmacies through its network of reliable partners in the MENA region.
• For more information, please visit: www.willach-pharmacy-solutions.com/ME
Automatic dispensing with a CONSIS H robot with automated
Automatic dispensing with CONSIS robots at Jaber Al Ahmad Hospital in Kuwait
Automatic dispensing with CONSIS robots at John Hopkins ARAMCO Hospital in Saudi Arabia
Malaysia External Trade Development Corporation
Strong Malaysian Presence at Arab Health 2025
Propelling Malaysian Medical Devices and Healthcare Services in the Middle East and North Africa (MENA) Region
Malaysia External Trade Development Corporation (MATRADE) continues its commitment to foster export opportunities for Malaysian medical devices and healthcare services in the Middle East and North Africa (MENA) region. The commitment is demonstrated by MATRADE in coordinating the participation of Malaysian companies in Arab Health 2025, marking MATRADE’s 21st consecutive year of active participation in this iconic event.
Over the years, Malaysian medical devices have gained global acceptance, supported by Malaysia’s position as the world’s top exporter of medical gloves and catheters. Malaysia has become well-known for producing surgical tools, syringes and needles, orthopaedic products, optical lenses, hospital furniture, blood transfusion sets,
dental dams, first aid kits etc.
Malaysia’s medical devices industry comprises of more than 200 manufacturers, of which 30 are multinationals that have made Malaysia their manufacturing base. This positions Malaysia as a medical device manufacturing hub in ASEAN as well as an outsourcing destination for many multinationals.
This year MATRADE will be featuring 11 companies showcasing a diverse range of innovative healthcare products and services including medical devices, digital healthcare solutions, pharmaceuticals and biotechnology to name a few.
Exports of medical devices were valued at US$6.6 billion in 2023. Over 90 percent of the medical devices manufactured in the country are exported, with over 50
percent of these going to the US, Germa ny, Japan, and China.
“MATRADE continues to provide a strategic avenue for Malaysian companies, enabling them to connect with numerous local and international suppliers and buyers across various product categories and stay abreast of the latest technological trends and innovations in the industry,” according to Mr. Megat Iskandar, Trade Commissioner of Malaysia to the UAE. He added that with the government aiming to implement Industry 4.0 initiatives, Malaysian businesses are looking to shift production into more value-added products and services, through embracing technology and enhancing research and development methods.
Megat Iskandar, Trade Commissioner of Malaysia to the UAE
Korea Health Industry Development Institute
Remedi Inc.
Remedi Inc. was founded in 2012 by Rena Lee, an MIT nuclear engineer, medical physicist and innovator with a lifelong desire to bring high quality, low-cost medical imaging and therapeutics to the world’s most medically underserved populations. Rena’s entrepreneurial mindset, deep knowledge of radiation technologies, and moral purpose served as the foundation for Remedi’s guiding philosophy.
Today, Remedi is a global leader in MedTech innovation, having successfully developed and commercialized a miniature, lightweight thermionic X-ray tube and high voltage power supply.
Our patented technologies have increased access to diagnostic imaging and therapy worldwide.
Handheld X-ray devices
Most importantly, we have revolutionized the portability of handheld X-ray devices and thus broadened the number of radiation applications within the medical, dental, veterinary, and industrial sectors.
REMEDI is a mission-driven organization ready to provide high quality, low cost, and effective imaging access to the world’s most underserved populations and all global citizens. A global leader in medical technology innovation, REMEDI has revolutionized the portability of handheld X-ray devices and broadened the number of applications within the medical, dental, veterinary and industrial sectors. REMEDI has 83 regulatory clearances with 7 products in 43 countries. We can save human lives together, using high intensity focused X-ray technology to drive innovation in imaging diagnostics and cancer treatment.
Medihub
Medihub is a leading developer of advanced medical devices, specializing in digital automatic syringes designed to enhance both patient safety and healthcare efficiency. Our flagship product, i-JECT, represents a breakthrough in injection technology by reducing injection pain, delivering precise and controlled dosages, and minimizing the risk of human error associated with manual injections. Additionally, i-JECT helps healthcare professionals prevent drug abuse and alleviates occupational hand and wrist pain often caused by repetitive manual injection procedures.
The i-JECT is a state-of-the-art syringe designed for precision and ease of use across a wide range of medical applications, including specialties such as dermatology, plas-
REMEX KA6 point-of-care imaging
We are introducing REMEX KA6, a handheld X-ray camera that will revolutionize point-of-care imaging. Weighing just 2.4 kg, it eliminates the need for large shielding rooms thanks to internal generator shielding, reducing scattered radiation. Safe, lightweight, and affordable, it offers ease of operation. With new battery tech, it can capture days’ worth of X-rays, perfect for busy practices, reducing retakes and saving time and money while maintaining high image quality. Specifically designed for situations where moving patients isn’t feasible, it provides quick and safe imaging for urgent diagnoses.
Exported to: (Asia) Japan, Philippines, Malaysia, Indonesia, Bangladesh, India, UAE, Iran, Maldives, Mongolia, Thailand, Iraq, etc. (Europe) Greece, Turkey, Israel, Italy, Ukraine, Netherlands, Russia, Germany, etc. (South America) Mexico, Peru, Panama, Colombia, etc. (Africa) Kenya, Ghana, South Africa, Egypt, Angola, Zambia, Côte d’Ivoire, Cameroon, Morocco, etc. (Others) United States, Australia.
For more information, visit: https://remedihc.com
tic surgery, dentistry, urology, orthopedics, and OBGYN. Its ergonomic design and advanced features ensure optimal control, making it a reliable choice for both healthcare professionals and patients. This device focuses on accuracy, minimizing patient discomfort, and improving overall outcomes.
Key features:
• Precise, consistent, and accurate drug delivery
• Pain reduction effect based on PCGT10‘’ (pain relief algorithm developed by Medihub)
• Ergonomic design helps prevent occupational diseases such as carpal tunnel syndrome
Through continuous R&D and a focus on global expansion, Medihub strives to redefine healthcare delivery, improving the safety and efficiency of medical procedures worldwide. Our mission is to create advanced solutions that address the evolving needs of both patients and medical professionals, ensuring better healthcare for all.
Exported to: Over 10 countries including the United States, Japan, UAE, Taiwan, Indonesia, and Ukraine.
For more information, visit: https://medihub.co.kr/en
LIVSMED
LIVSMED is a global innovator in the medical device industry, dedicated to advancing surgical solutions through cuttingedge technology and design. The company has achieved a significant milestone with the development of ‘ArtiSential’, the world’s first multi-joint, multi-degree-offreedom laparoscopic surgical instrument, which is redefining the standards of minimally invasive surgery.
The name ‘ArtiSential’ derives from the combination of “Articulation” and “Essential”, embodying its advanced articulation capabilities and indispensable role in modern surgical procedures. This groundbreaking device offers intuitive manipulation through wrist-like joints, uniquely designed to replicate the complex movements of the human hand. By enabling precise control within confined surgical sites, ArtiSential empowers surgeons to perform intricate tasks such as incision, suturing, dissection, anastomosis, and bloodless resection. Unlike conventional straight instruments, its design enhances accessibility to challenging areas, including tumour tissues and deep lesions, ensuring superior surgical outcomes.
Since its market introduction in 2018, ArtiSential has garnered international
KIMSBIO
KIMSBIO Co., Ltd. researches and manufactures innovative medical devices aimed at the minimally invasive surgery market. The company manufactures its products in a Class 100,000 cleanroom, ensuring compliance with strict cleanliness and precision standards. Additionally, we have KGMP (Korea Good Manufacturing Practice) and ISO13485:2016 certifications, maintaining high standards of quality and regulatory compliance.
The non-absorbable polymer ligating clip, CURE LOCK, is a surgical clip that externally compresses blood vessels or tissues during surgical procedures to stop bleeding. It is available in ML, L, and XL sizes, and you can select the size according to the size of the blood vessel or tissue to stop bleeding.
D-Cure Fix Plus is a medical device that
acclaim for its unparalleled performance and innovation. LIVSMED has rapidly expanded its global footprint, currently operating in 54 countries through three subsidiaries and 32 distributors. The company’s reach spans key markets such as the United States, Japan, the United Kingdom, and Australia, reflecting its commitment to delivering advanced medical technologies worldwide.
LIVSMED’s contributions to the medical field have been widely recognized. The company was honoured with the South Korean Minister of Health and Welfare Award in 2018 and designated as an innovative medical device company by the Ministry of Health and Welfare in 2020. It was also selected as a pre-
unicorn company and achieved the highest ranking in technology and business evaluations by the Ministry of SMEs and Startups.
Through close collaboration with leading hospitals and comprehensive training programmes, LIVSMED ensures seamless adoption of its technology. As the global healthcare industry evolves, LIVSMED remains steadfast in its mission to pioneer minimally invasive surgical solutions, driving innovation and enhancing patient care worldwide.
Exported to: Germany, United States, Taiwan, China, Japan, etc.
• For more information, visit: https://livsmed.com
combines the functions of a non-invasive skin closure device and a catheter securement device. It is a product that uses ties and buttons to easily and conveniently fix drainage tubes and maintain skin sutures, and minimizes skin irritation by using hydrocolloid.
The Ureter Access Sheath is a medical device used in the treatment of kidney stones and urinary tract stones. It provides a passage for the insertion of a flexible ureteroscope and features a hydrophilic coating to ensure smooth insertion during surgery.
KIMSBIO is committed to providing high-quality, reliable medical devices for the advancement of minimally invasive surgery. The company continually develops innovative products that enhance clinical outcomes. All products are developed using the latest technologies and are rigorously tested to meet international standards.
Exported to: Vietnam
• For more information, visit: www.kimsbio.net
Korea Health Industry Development Institute
Dyne Medical Group Inc.
Forward with standards. This is our essence and approach towards life.
At Dyne Medical Group, we provide products and solutions that consider all aspects of the medical environment based on the mission and responsibility that medical professionals have towards patients. Our unwavering standard ultimately serves the goal of saving more lives and contributing to a happy life for all people everywhere.
URUS™ Ureteroscope: Designed with precision with a pioneering 6 o’clock working channel
Our flagship product, the URUS™ Ureteroscope, is a single-use, flexible ureteroscope system developed with a focus on patient safety and operational efficiency. Each device is pre-sterilized, helping to reduce the risk of cross-contamination and optimize workflow in healthcare settings. (Certified US FDA 510(k) and Korea MFDS)
A key innovation of the URUS™ is its 6 o’clock working channel, a distinctive feature in ureteroscope design. Unlike traditional 3 o’clock or 9 o’clock chan-
LN Robotics
Founded in 2019, LN Robotics Inc. was established in collaboration with the medical staff of Asan Medical Center with the aim of commercializing medical robots to address the unmet needs of clinical sites. Our main focus has been redefining cardiovascular intervention through advanced robotics incorporating innovative technologies such as haptics, artificial intelligence, big data, and biotechnology, with significant input from clinical experts. We possess optimized capabilities for product design, development, evaluation, pre-clinical trials, and clinical trials through joint research with clinical medical staff.
Advanced Vascular Intervention Assistive Robot
Our first medical robot, named AVIAR (Advanced Vascular Intervention Assis-
nels, the 6 o’clock channel offers an improved balance of view, instrument control, and user ergonomics. This configuration enhances visibility and facilitates precise navigation, during the urological procedures.
In addition, we are introducing Port-C™, an innovative endoscope connector designed for accessory ports. Port-C™ features an adjustable range of 0 to 6 mm, allowing precise alignment of laser and basket instruments without adjusting irrigation seals. This patented product, already available in Korea, is drawing interest from surgeons and industry experts for its potential to improve procedural efficiency.
Group collaborates with globally recognized partners such as EMS and Wellead to provide comprehensive solutions for kidney stone treatment. These partnerships enable us to integrate advanced technologies that support both patient outcomes and clinical workflows.
Exported to: Indonesia
Expanding the future of urology
Leveraging our expertise, Dyne Medical
For more information, visit: https://dynemedical.co.kr
tive Robot), is designed to help treat patients with vascular diseases. The current focus is on PCI (Percutaneous Coronary Intervention) to treat cardiovascular diseases, which are one of the leading causes of death worldwide. We pursue beyond the limits of conventional manual techniques to improve the implementation of robotic intervention procedures. The key benefits of AVIAR are to reduce radiation for clinicians and patients and to minimize interoperator variance in the procedure.
In 2023, we obtained Korea’s first approval for a cardiovascular interventional
procedure robot. We aim to install and sell it in hospitals in Korea by the first half of 2025 and to obtain FDA approval by 2026 and CE approval by 2027.
• For more information, visit: https://lnrobo.com
HNT MEDICAL
Key technologies
HNT MEDICAL Co. Ltd. specializes in shock wave technology for lithotripsy. We have eight related technology patents. We have the technology to produce both the original EH (electro-hydraulic) type and the latest EM (electro-magnetic) cylinder type technology. In particular, the EM cylinder type is the latest 4th generation technology. It enables a method of tightly winding an electromagnetic coil and applying high voltage to generate shock waves. Shock wave generation is the most stable method and consumables management is also reasonable. In addition, it has the advantage of a wider treatment area and superior treatment effects compared to the previous generation technology of the piezo type.
Furthermore, we have ‘multi-focus’ head technology. This is a patented technology that only HNT has – not only in
Caimi
Caimi Co., Ltd. was established in 2020.
The company develops artificial intelligence-based digestive cancer and lesion diagnostic equipment. In August 2023, Caimi completed research and development of medical devices that detect various lesions including malignant tumours through realtime analysis of gastrointestinal endoscopy image data and released an artificial intelligence medical device called “ALPHAON.”
Starting with the artificial intelligence medical device “ALPHAON STOMACH” for the upper gastrointestinal tract in 2023, Cami then developed “ALPHAON COLON” equipped with colon lesion function in 2024, allowing the detection of lesions in the oesophagus, stomach and colon at the same time. In addition, we are preparing various additional services such as ALPHAON-T, an educational service, by securing various clinical data.
Caimi’s Alphaon automatically marks the lesion or suspected lesion area in the endoscope view using an AI function and provides the location in real time using Navigation Mode.
These functions can help inexperienced
Korea, but across the world (Patent Registration No. 10-1234682 / Patent name: Multiple Center Frequency Shock Wave Generator).
The devices are easy to use as they don’t require an applicator for treatment; they enable the formation of a three-dimensional focal zone, and they have technology that minimizes microdamage.
Main sales and exporting countries
We have supplied our products to major university hospitals, government sports science centres, and professional sports teams in Korea. We are also exporting them to various countries including Denmark, Italy, Austria, Uzbekistan, Sudan, Vietnam, etc.
Main products
We have launched products for various specialties, including orthopaedics, urology, OB-GYN, and dermatology.
UROSTONE: New product. Electromagnetic type extracorporeal shock wave lithotripter. equipped with world’s first AI features; 10-way movable patient table.
CENOWAVE: Electro-magnetic type focused-shock wave therapy; patented multifocus head; direct water cooling.
CoCowave+: The first Korean extracorporeal shock wave therapy device for animals approved by the Korea Animal and Plant Quarantine Agency.
Exported to: Denmark, Italy, Austria, Uzbekistan, Sudan, Vietnam, etc. For more information, visit: http://hntmedical.kr
specialists by assisting them to identify lesions on par with those with more than 10 years of experience in endoscopy.
Alphaon is certified as Korean medical device level 1 and 2 for gastrointestinal tract and Korean medical device level 2 for colon. We are preparing for US FDA certification and overseas expansion.
Caimi signed an MoU with a hospital in Dubai in October 2023, and signed an MoU with ECO Waller José Guimara Cavaleiri of Chemol in August 2024. Caimi is currently in the process of establishing a Brazilian corporation to enter Brazil and is preparing for ISO 13485 certification review.
Key products
ALPHAON
Technology and features
1. Main video frame
interlocked endoscopic image realtime display
Image Display of endoscope system linked to alpha when the AI analysis
function is activated, real-time display of lesion areas in the endoscope area.
2. Navigation mode
Provide real-time screening location
The real-time sign of the examination location (check the examination area and prevent omission)
3. Marking of the lesion site
Automatic marking of lesion or suspected lesion areas
As a result of AI analysis, it is possible to check the results of multiple placement/ scrolling application at the top of the latest real-time cover analysis results.
Exported to: Brazil
• For more information, visit: http://www.caimi.co.kr
Korea Health Industry Development Institute
Running mate for a healthier tomorrow in Korea
The Korea Health Industry Development Institute (KHIDI) is a governmentaffiliated organization, under the Ministry of Health and Welfare of Korea. KHIDI carries out national affairs on the goals of fostering the domestic health industry, strengthening its international competitiveness, and consequently improving people’s quality of life in order to contribute to the advancement of Korea as a global bio and digital health hub.
A consensus on the importance of the health industry has enabled Korea to build a safe and healthy society protected against the health risks derived from emerging infectious diseases and a superaged society.
To support the health industry for the
healthy future of our families and neighbours – this is the role and calling of KHIDI.
Showcasing Korea’s cutting-edge MedTech at the K-MedTech Experience Pavilion, Arab Health 2025
KHIDI is committed to advancing high-quality, technologically superior Korean medical devices in the global market. As part of these efforts, KHIDI will participate in Arab Health 2025, showcasing the latest advancements in Korea’s innovative MedTech industry.
At the K-MedTech Experience Pavilion, eight leading companies with promising technologies will be on-site to demonstrate their state-of-the-art medical device products. Attendees will have
the unique opportunity to explore these innovations firsthand through live demonstrations.
Company representatives and experienced medical practitioners will be present to answer questions, provide in-depth explanations, and discuss the future value and impact of these groundbreaking solutions.
This event offers a rare opportunity to gain insights into Korea’s innovative MedTech sector, interact directly with cutting-edge technologies, and experience the exceptional capabilities of products designed to shape the future of healthcare.
We invite you to visit the KHIDI booth at Arab Health and discover how Korean MedTech is redefining healthcare innovation on a global scale.
• For more information, visit: https://www.khidi.or.kr/eps
The Back Page
Deep sleep’s brain-cleaning system revealed in landmark study
Scientists have discovered how deep sleep drives the brain’s waste clearance – or glymphatic – system through rhythmic releases of norepinephrine, offering new insights into restorative sleep and potential implications for neurodegenerative diseases.
Danish researchers have made a groundbreaking discovery about how the brain cleans itself during deep sleep, revealing that a molecule called norepinephrine orchestrates a rhythmic “pumping” system that flushes out waste products. The study, published in Cell on January 8, demonstrates how this essential housekeeping process could be disrupted by common sleep medications.
The research team, led by Professor Maiken Nedergaard from the University of Copenhagen and University of Rochester, found that during deep sleep, the brainstem releases tiny waves of norepinephrine approximately every 50 seconds. This triggers blood vessels to contract and generate slow pulsations that create a rhythmic flow in the surrounding fluid, effectively washing away toxic waste products.
“It’s like turning on the dishwasher before you go to bed and waking up with a clean brain,” said Nedergaard. “We’re essentially asking what drives this process and trying to define restorative sleep based on glymphatic clearance.”
Impact of sleep medication on brain cleaning
In a concerning finding, the researchers discovered that the commonly prescribed sleep aid zolpidem (Ambien) significantly
impairs this cleaning process. When mice were given zolpidem, the norepinephrine waves during deep sleep were 50% lower than in naturally sleeping mice. Although the medicated mice fell asleep faster, fluid transport into the brain dropped by more than 30%.
Lead author Natalie Hauglund of the University of Copenhagen and University of Oxford emphasised the implications: “More and more people are using sleep medication, and it’s really important to know if that’s healthy sleep. If people aren’t getting the full benefits of sleep, they should be aware of that so they can make informed decisions.”
The science behind brain cleaning
The study reveals that the brain’s waste removal system, known as the glymphatic system, relies on the precise timing of norepinephrine release to function effectively. During deep sleep, blood vessels contract and relax in a coordinated manner, creating a pumping effect that propels cerebrospinal fluid through brain tissue to remove accumulated waste products.
The researchers note in their discussion that this process is particularly important as the brain lacks conventional lymphatic vessels found elsewhere in the body. The newly discovered mechanism explains how the brain compensates for this ab-
sence through the coordinated action of blood vessels and fluid dynamics.
Clinical implications
The findings have significant implications for understanding how poor sleep may contribute to neurological disorders like Alzheimer’s disease. The authors suggest that the arterial “pumping” of cerebrospinal fluid likely functions optimally when cerebral vessels retain high elasticity. Stiffening of the vascular wall, whether due to chronic hypertension or vascular amyloidosis, would reduce the amplitude of vascular volume changes, thereby decreasing glymphatic clearance.
This research also raises important questions about the long-term use of sleep medications that might interfere with the brain’s natural cleaning mechanism. The authors emphasise that while zolpidem reduces the latency to sleep, it interferes with normal sleep architecture and suppresses glymphatic flow in mice.
The team believes these findings likely apply to humans, who also possess a glymphatic system, though this requires further testing. Similar norepinephrine waves, blood flow patterns, and brain fluid movements have been observed in human studies.
“Now we know norepinephrine is driving the cleaning of the brain, we may figure out how to get people a long and restorative sleep,” concluded Nedergaard.
Reference: Hauglund, N. L., Andersen, M., Tokarska, K., et. al. Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep. Cell, 188, 1-17. January 8, 2025. https://doi.org/10.1016/j.cell.2024.11.027
